1
|
Yin X, Davi R, Lamont EB, Thaker PH, Bradley WH, Leath CA, Moore KM, Anwer K, Musso L, Borys N. Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. JCO Clin Cancer Inform 2023; 7:e2200103. [PMID: 36608308 DOI: 10.1200/cci.22.00103] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
PURPOSE To inform continued development of the novel immune agent GEN-1, we compared ovarian cancer patients' end points from a neoadjuvant single-arm phase IB study with those of similar historic clinical trial (HCT) patients who received standard neoadjuvant chemotherapy. METHODS Applying OVATION-1 trial (ClinicalTrials.gov identifier: NCT02480374) inclusion and exclusion criteria to Medidata HCT data, we identified historical trial patients for comparison. Integrating patient-level Medidata historic trial data (N = 41) from distinct neoadjuvant ovarian phase I-III trials with patient-level OVATION-1 data (N = 18), we selected Medidata patients with similar baseline characteristics as OVATION-1 patients using propensity score methods to create an external control arm (ECA). RESULTS Fifteen OVATION-1 patients (15 of 18, 83%) were matched to 15 (37%, 15 of 41) Medidata historical trial control patients. Matching attenuated preexisting differences in attributes between the groups. The median progression-free survival time was not reached by the OVATION-1 group and was 15.8 months (interquartile range, 11.40 months to nonestimable) for the ECA. The hazard of progression was 0.53 (95% CI, 0.16 to 1.73), favoring GEN-1 patients. Compared with ECA patients, OVATION-1 patients had more nausea, fatigue, chills, and infusion-related reactions. CONCLUSION Comparing results of a single-arm early-phase trial to those of a rigorously matched HCT ECA yielded insights regarding comparative efficacy prior to a randomized controlled trial. The effect size estimate itself informed both the decision to continue development and the randomized phase II trial (ClinicalTrials.gov identifier: NCT03393884) sample size. The work illustrates the potential of HCT data to inform drug development.
Collapse
Affiliation(s)
- Xiang Yin
- Medidata AI, Medidata Solutions, a Dassault Systèmes Company, New York, NY
| | - Ruthanna Davi
- Medidata AI, Medidata Solutions, a Dassault Systèmes Company, New York, NY
| | - Elizabeth B Lamont
- Medidata AI, Medidata Solutions, a Dassault Systèmes Company, New York, NY
| | - Premal H Thaker
- Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, MO
| | | | - Charles A Leath
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
| | - Kathleen M Moore
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.,Sarah Cannon Research Institute, Nashville, TN
| | | | | | | |
Collapse
|
2
|
Yin X, Davi R, Lamont EB, Thaker PH, Bradley WH, Leath CA, Moore KM, Anwer K, Musso L, Borys N. Abstract 1025: Phase Ib trial single-arm efficacy estimates via comparison to a historical clinical trial synthetic control arm. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Innovations in data science and trial design have catalyzed novel clinical research methods which may inform the future success of new experimental therapies more efficiently than previously believed. To guide development of the novel immune agent GEN-1, we compared endpoints experienced by patients from a recent neoadjuvant single-arm phase Ib study of GEN-1 plus standard chemotherapy to those of similar historical clinical trial patients in receipt of standard chemotherapy alone.
Methods: To compare safety and efficacy endpoints following first-line neoadjuvant weekly GEN-1 immunotherapy and carboplatin and paclitaxel to standard first-line neoadjuvant carboplatin and paclitaxel in women with advanced ovarian cancer, we first applied key OVATION-1 trial (NCT02480374) inclusion and exclusion criteria to the Medidata Enterprise Data Store (MEDS) data to identify candidate historical clinical trial patients for comparison. We standardized and integrated patient-level MEDS data (N=41) from distinct phase I-III trials (enrollment years 2015-2016) with patient-level OVATION-1 data (N=18). Standard propensity score methods were used to identify MEDS patients who appeared similar to OVATION-1 patients to create a synthetic control arm (SCA).
Results: Fifteen OVATION-1 patients (15/18, 83%) were matched to 15 (37%, 15/41) MEDS historical trial control patients. Matching attenuated pre-existing differences in attributes between the OVATION-1 and MEDS patients. The median progression-free survival time was not reached by the OVATION-1 group and was 15.8 months for the SCA. The hazard of progression for the OVATION-1 group relative to the SCA was 0.53 (95% CI 0.16, 1.73). Fourteen of 15 OVATION-1 patients (93.3%) and 15 of the SCA patients (100%, 15/15) had at least one MedDRA toxicity. Compared to SCA patients, OVATION-1 patients had a slightly higher incidence in nausea (OVATION-1 73.3%; SCA 53.3%), fatigue (OVATION-1 73.3%; SCA 33.3%), anorexia (OVATION-1 46.7%; SCA 13.3%), chills (OVATION-1 26.7%; SCA 6.7%), and infusion-related reaction (OVATION-1 26.7%; SCA 0%).
Conclusions: The comparison of patient endpoints from a single-arm phase Ib trial to a historical clinical trial SCA provided informative and relatively reliable estimates of efficacy endpoints which were used to inform GEN-1’s expected effect study size in the phase II setting. This information led to a decrease in the number of planned patients for the subsequent randomized phase II trial. More broadly, this approach supports the ability of historical clinical trial patient comparisons to inform drug development via trial design, something which may further increase the scientific value of early phase trials.
Citation Format: Xiang Yin, Ruthanna Davi, Elizabeth B. Lamont, Premal H. Thaker, William H. Bradley, Charles A. Leath, Kathleen M. Moore, Khursheed Anwer, Lauren Musso, Nicholas Borys. Phase Ib trial single-arm efficacy estimates via comparison to a historical clinical trial synthetic control arm [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1025.
Collapse
Affiliation(s)
- Xiang Yin
- 1Medidata Solutions, a Dassaults Systemes Company, New York, NY
| | - Ruthanna Davi
- 1Medidata Solutions, a Dassaults Systemes Company, New York, NY
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Gunderson CC, Radhakrishnan R, Gomathinayagam R, Husain S, Aravindan S, Moore KM, Dhanasekaran DN, Jayaraman M. Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis. Biomark Insights 2022; 17:11772719221088404. [PMID: 35370397 PMCID: PMC8966103 DOI: 10.1177/11772719221088404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 02/10/2022] [Indexed: 11/17/2022] Open
Abstract
Clinical management of gynecological cancer begins by optimal debulking with first-line platinum-based chemotherapy. However, in ~80% patients, ovarian cancer will recur and is lethal. Prognostic gene signature panel identifying platinum-resistance enables better patient stratification for precision therapy. Retrospectively collected serum from 11 "poor" (<6 months progression free interval [PFI]) and 22 "favorable" (>24 months PFI) prognosis patients, were evaluated using circulating cell-free DNA (cfDNA). DNA from both groups showed 50 to 10 000 bp fragments. Pairwise analysis of sequenced cfDNA from patients showed that gene dosages were higher for 29 genes and lower for 64 genes in poor than favorable prognosis patients. Gene ontology analysis of higher dose genes predominantly grouped into cytoskeletal proteins, while lower dose genes, as hydrolases and receptors. Higher dosage genes searched for cancer-relatedness in Reactome database indicated 15 genes were referenced with cancer. Among them 3 genes, TGFBR2, ZMIZ2, and NRG2, were interacting with more than 4 cancer-associated genes. Protein expression analysis of tumor samples indicated that TGFBR2 was downregulated and ZMIZ2 was upregulated in poor prognosis patients. Our results indicate that the cfDNA gene dosage combined with protein expression in tumor samples can serve as gene signature panel for prognosis determination amongst ovarian cancer patients.
Collapse
Affiliation(s)
- Camille C Gunderson
- Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | | | - Rohini Gomathinayagam
- Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Sanam Husain
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Sheeja Aravindan
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Kathleen M Moore
- Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Danny N Dhanasekaran
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA,Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Muralidharan Jayaraman
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA,Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA,Muralidharan Jayaraman, Department of Cell Biology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 975 NE 10th Street, BRC416, Oklahoma City, OK 73104, USA.
| |
Collapse
|
4
|
John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecol Oncol 2021; 164:202-207. [PMID: 34862065 DOI: 10.1016/j.ygyno.2021.10.077] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 10/07/2021] [Accepted: 10/13/2021] [Indexed: 11/04/2022]
Abstract
OBJECTIVES BRCA 1 or 2 mutation carriers have increased risk of developing breast cancer (BC) and serous epithelial ovarian cancer (EOC). The incidence of BC over time after EOC is unknown. Optimal BC surveillance for BRCA mutation carriers following EOC has not been defined. METHODS A multi-institutional retrospective chart review was performed. Patients with BRCA -associated EOC diagnosed between 1996 and 2016 were followed for an average of 80 months. Women with previous bilateral mastectomy were excluded; women with prior BC and an intact breast were included. Descriptive statistics, Chi Square, and univariate survival analysis were performed. RESULTS 184 patients with BRCA -associated EOC were identified. Eighteen (10%) were diagnosed with BC a median of 48 months following EOC. Two (1%) with prior BC developed contralateral BC and 16 (9%) developed primary BC. The majority of BC (55%) was diagnosed 3 years following EOC. The 3-, 5- and 10-year incidence of BC was 5.6%, 9.5% and 33.3%. Annual mammography was performed in 43% and MRI in 34%. Twenty-eight (15%) women underwent risk-reducing mastectomy (RRM). There was no statistically significant difference in BC screening between women with, and without, a prior BC. BC was most commonly detected on mammogram. Three (17%) women had occult BC at the time of RRM. Nine (50%) had DCIS, and 8 (44%) had stage I/II BC. Median 5- and 10-year survival was 68% and 43% and was comparable between groups. CONCLUSIONS Ten percent of women developed BC after EOC. The incidence of BC following EOC in BRCA carriers increases over time, and surveillance is recommended given their enhanced survival of EOC. Timely genetic testing for women with EOC is imperative to better triage BC screening resources and treatment.
Collapse
Affiliation(s)
- Catherine S John
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
| | - Abigail Fong
- Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Rodrigo Alban
- Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Jessica Gillen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
| | - Kathleen M Moore
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
| | - Christine S Walsh
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Andrew J Li
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - B J Rimel
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Farin Amersi
- Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Ilana Cass
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| |
Collapse
|
5
|
Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. Am Surg 2020; 86:1243-1247. [DOI: 10.1177/0003134820964208] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BRCA1 or 2 mutations result in higher cancer risk for breast cancer (BC) and epithelial ovarian cancer (EOC) for carriers than exists in the general population. Optimal breast imaging surveillance in these patients has not been well defined. An Institutional Review Board-approved, multi-institutional retrospective chart review was performed. Patients diagnosed with BRCA-associated EOC between 1990-2015 were identified; demographic and clinical data were collected and analyzed. 192 BRCA mutation–positive patients with EOC were identified. 16/192 (8.3%) women were diagnosed with BC following EOC, at a median of 50 (range 5-327) months following EOC diagnosis and median age 59.5 (45-84) years. Breast cancer was most commonly detected on mammogram 7/16 (44%) or clinical exam 7/16 (44%). 2/16 (12.5%) had occult BC found during risk-reducing mastectomy. 14 (88%) had early-stage (0-2) disease. At mean follow-up of 8.1 years, 6 (37.5%) patients with BC following EOC had died due to EOC. The risk of BC diagnosis following EOC in BRCA mutation carriers is low; most of these BCs are early stage and diagnosed with mammography or physical exam. Overall, survival in BRCA mutation carriers is dominated by EOC-related mortality. Breast cancer surveillance in BRCA mutation carriers following EOC should prioritize nonsurgical strategies.
Collapse
Affiliation(s)
- Abigail Fong
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Ilana Cass
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | | | | | | | | | | | - Andrew J. Li
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | | | | | - Farin Amersi
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
6
|
Hunnam JC, Moore KM, Daniel P, Stevenson MA, Salmon SE. Classical swine fever in Victorian domestic pigs: evidence of disease freedom. Aust Vet J 2019; 97:447-451. [PMID: 31475336 DOI: 10.1111/avj.12871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 07/08/2019] [Accepted: 07/14/2019] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Australia is currently regarded as free of classical swine fever (CSF), a highly contagious disease of pigs caused by a pestivirus. This study aimed to provide additional evidence that the Victorian domestic pig population is free of CSF. DESIGN A structured representative sero-prevalence survey of Victorian domestic pigs at slaughter. METHOD Three-hundred and ninety-one pigs from 23 holdings were sampled at the time of slaughter between March 2016 and October 2017. RESULTS All samples were negative for CSF virus Ab on ELISA. Because of uncertainty in the sensitivity of the CSF Ab ELISA, estimates of the true prevalence of CSF were calculated using Bayesian methods. The median and upper bound of the 95% credible intervals for the true prevalence of CSF was zero when the diagnostic sensitivity of the CSF Ab ELISA was assumed to range from 0.75 to 0.95. CONCLUSION These results provide evidence that the population of domestic pigs in Victoria in 2016-2017 was free of CSF.
Collapse
Affiliation(s)
- J C Hunnam
- Chief Veterinary Officer's Unit, Agriculture Victoria, Department of Economic Development, Jobs, Transport and Resources, 475 Mickleham Road, Attwood, Victoria, 3049, Australia
| | - K M Moore
- Chief Veterinary Officer's Unit, Agriculture Victoria, Department of Economic Development, Jobs, Transport and Resources, 475 Mickleham Road, Attwood, Victoria, 3049, Australia
| | - P Daniel
- Chief Veterinary Officer's Unit, Agriculture Victoria, Department of Economic Development, Jobs, Transport and Resources, 475 Mickleham Road, Attwood, Victoria, 3049, Australia
| | - M A Stevenson
- Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Parkville, Victoria, 3010, Australia
| | - S E Salmon
- Chief Veterinary Officer's Unit, Agriculture Victoria, Department of Economic Development, Jobs, Transport and Resources, 475 Mickleham Road, Attwood, Victoria, 3049, Australia
| |
Collapse
|
7
|
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019. [PMID: 30676622 DOI: 10.1001/jamaoncol.2018.6258] [] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti-programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer. Design, Setting, and Participants In an expansion cohort of a phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian cancer who had received chemotherapy including a platinum agent were enrolled between November 6, 2013, and August 27, 2015. Statistical analysis was performed from December 31, 2016, to October 9, 2018. Intervention Patients received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. Main Outcomes and Measures Prespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety. Results A total of 125 women (median age, 62.0 years [range, 27-84 years]) who had received a median of 3 prior lines of treatment (range, 0-10) for advanced disease were enrolled in the study. Patients received avelumab for a median of 2.8 months (range, 0.5-27.4 months), with a median follow-up of 26.6 months (range, 16-38 months). A confirmed objective response occurred in 12 patients (9.6%; 95% CI, 5.1%-16.2%), including a complete response in 1 patient (0.8%) and a partial response in 11 patients (8.8%). The 1-year progression-free survival rate was 10.2% (95% CI, 5.4%-16.7%) and median overall survival was 11.2 months (95% CI, 8.7-15.4 months). Infusion-related reactions occurred in 25 patients (20.0%). Other frequent treatment-related adverse events (any grade event occurring in ≥10% of patients) were fatigue (17 [13.6%]), diarrhea (15 [12.0%]), and nausea (14 [11.2%]). Grade 3 or higher treatment-related adverse events occurred in 9 patients (7.2%), of which only the level of lipase increased (3 [2.4%]) occurred in more than 1 patient. Twenty-one patients (16.8%) had an immune-related adverse event of any grade. No treatment-related deaths occurred. Conclusions and Relevance Avelumab demonstrated antitumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer. Trial Registration ClinicalTrials.gov identifier: NCT01772004.
Collapse
Affiliation(s)
- Mary L Disis
- Department of Medicine, UW Medicine Cancer Vaccine Institute, University of Washington School of Medicine, Seattle.,Editor
| | - Matthew H Taylor
- Knight Cancer Institute, Oregon Health and Science University, Portland
| | - Karen Kelly
- Davis Comprehensive Cancer Center, University of California, Sacramento
| | - J Thaddeus Beck
- Medical Oncology, Highlands Oncology Group, Fayetteville, Arkansas
| | - Michael Gordon
- HonorHealth Research Institute, HonorHealth Virginia G. Piper Cancer Care Network, Scottsdale, Arizona
| | - Kathleen M Moore
- Peggy and Charles Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, University of Oklahoma, Oklahoma City
| | - Manish R Patel
- Medical Oncology, Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota
| | - Jorge Chaves
- Medical Oncology, Northwest Medical Specialties, Tacoma, Washington
| | - Haeseong Park
- Division of Oncology, Washington University School of Medicine, St Louis, Missouri
| | - Alain C Mita
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Erika P Hamilton
- Medical Oncology, Tennessee Oncology, Sarah Cannon Research Institute, Nashville
| | - Christina M Annunziata
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| | - Hans Juergen Grote
- Clinical Biomarkers and Companion Diagnostics, Merck KGaA, Darmstadt Germany
| | | | - Jaspreet Grewal
- Global Clinical Development, EMD Serono, Billerica, Massachusetts.,currently at Hematology, Norton Healthcare, Louisville, Kentucky
| | - Vikram Chand
- Global Clinical Development, EMD Serono, Billerica, Massachusetts.,currently at Global Development, AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland
| | - James L Gulley
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
8
|
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019; 5:393-401. [PMID: 30676622 PMCID: PMC6439837 DOI: 10.1001/jamaoncol.2018.6258] [Citation(s) in RCA: 276] [Impact Index Per Article: 55.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 10/23/2018] [Indexed: 12/26/2022]
Abstract
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti-programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer. Design, Setting, and Participants In an expansion cohort of a phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian cancer who had received chemotherapy including a platinum agent were enrolled between November 6, 2013, and August 27, 2015. Statistical analysis was performed from December 31, 2016, to October 9, 2018. Intervention Patients received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. Main Outcomes and Measures Prespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety. Results A total of 125 women (median age, 62.0 years [range, 27-84 years]) who had received a median of 3 prior lines of treatment (range, 0-10) for advanced disease were enrolled in the study. Patients received avelumab for a median of 2.8 months (range, 0.5-27.4 months), with a median follow-up of 26.6 months (range, 16-38 months). A confirmed objective response occurred in 12 patients (9.6%; 95% CI, 5.1%-16.2%), including a complete response in 1 patient (0.8%) and a partial response in 11 patients (8.8%). The 1-year progression-free survival rate was 10.2% (95% CI, 5.4%-16.7%) and median overall survival was 11.2 months (95% CI, 8.7-15.4 months). Infusion-related reactions occurred in 25 patients (20.0%). Other frequent treatment-related adverse events (any grade event occurring in ≥10% of patients) were fatigue (17 [13.6%]), diarrhea (15 [12.0%]), and nausea (14 [11.2%]). Grade 3 or higher treatment-related adverse events occurred in 9 patients (7.2%), of which only the level of lipase increased (3 [2.4%]) occurred in more than 1 patient. Twenty-one patients (16.8%) had an immune-related adverse event of any grade. No treatment-related deaths occurred. Conclusions and Relevance Avelumab demonstrated antitumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer. Trial Registration ClinicalTrials.gov identifier: NCT01772004.
Collapse
Affiliation(s)
- Mary L. Disis
- Department of Medicine, UW Medicine Cancer Vaccine Institute, University of Washington School of Medicine, Seattle
- Editor, JAMA Oncology
| | - Matthew H. Taylor
- Knight Cancer Institute, Oregon Health and Science University, Portland
| | - Karen Kelly
- Davis Comprehensive Cancer Center, University of California, Sacramento
| | - J. Thaddeus Beck
- Medical Oncology, Highlands Oncology Group, Fayetteville, Arkansas
| | - Michael Gordon
- HonorHealth Research Institute, HonorHealth Virginia G. Piper Cancer Care Network, Scottsdale, Arizona
| | - Kathleen M. Moore
- Peggy and Charles Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, University of Oklahoma, Oklahoma City
| | - Manish R. Patel
- Medical Oncology, Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota
| | - Jorge Chaves
- Medical Oncology, Northwest Medical Specialties, Tacoma, Washington
| | - Haeseong Park
- Division of Oncology, Washington University School of Medicine, St Louis, Missouri
| | - Alain C. Mita
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Erika P. Hamilton
- Medical Oncology, Tennessee Oncology, Sarah Cannon Research Institute, Nashville
| | - Christina M. Annunziata
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| | - Hans Juergen Grote
- Clinical Biomarkers and Companion Diagnostics, Merck KGaA, Darmstadt Germany
| | | | - Jaspreet Grewal
- Global Clinical Development, EMD Serono, Billerica, Massachusetts
- currently at Hematology, Norton Healthcare, Louisville, Kentucky
| | - Vikram Chand
- Global Clinical Development, EMD Serono, Billerica, Massachusetts
- currently at Global Development, AstraZeneca Pharmaceuticals LP, Gaithersburg, Maryland
| | - James L. Gulley
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
9
|
Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol 2017; 146:101-108. [PMID: 28527672 DOI: 10.1016/j.ygyno.2017.05.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 05/05/2017] [Accepted: 05/07/2017] [Indexed: 11/28/2022]
Abstract
PURPOSE Long-term survival of women with advanced-stage ovarian cancer is relatively rare. Little is known about quality of life (QOL) and survivorship concerns of these women. Here, we describe QOL of women with advanced-stage ovarian cancer surviving for 8.5 years or longer and compare women with 0-1 recurrence to those with multiple recurrences. METHODS Participants (n=56) recruited from 5 academic medical centers and the Ovarian Cancer Research Fund Alliance completed surveys regarding QOL (FACT-O), mood (CESD), social support (SPS), physical activity (IPAQ-SF), diet, and clinical characteristics. Median survival was 14.0 years (range 8.8-33.3). RESULTS QOL and psychological adjustment of long-term survivors was relatively good, with mean FACT-G scores (multiple recurrences: 80.81±13.95; 0-1 recurrence: 89.05 ±10.80) above norms for healthy community samples (80.1±18.1). Survivors with multiple recurrences reported more compromised QOL in domains of physical and emotional well-being (p <.05), and endorsed a variety of physical and emotional concerns compared to survivors with 0-1 recurrence. Difficulties in sexual functioning were common in both groups. Almost half (43%) of the survivors reported low levels of physical activity. CONCLUSIONS Overall, women with advanced-stage ovarian cancer who have survived at least 8.5 years report good QOL and psychological adjustment. QOL of survivors with multiple recurrences is somewhat impaired compared to those with 0-1 recurrence. Limitations include a possible bias towards participation by healthier survivors, thus under-representing the level of compromise in long-term survivors. Health care practitioners should be alert to psychosocial issues faced by these long-term survivors to provide interventions that enhance QOL.
Collapse
Affiliation(s)
- Susan K Lutgendorf
- Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA, USA; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, USA; Department of Urology, University of Iowa, Iowa City, IA, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
| | - Eileen Shinn
- Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | - Jeanne Carter
- Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Gynecology Service, Department of Psychiatry and Surgery Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Susan Leighton
- Ovarian Cancer Research Fund Alliance, Washington, DC, United States
| | - Keith Baggerly
- Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | - Michele Guindani
- Department of Biostatistics, Division of Quantitative Sciences, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | - Bryan Fellman
- Department of Biostatistics, Division of Quantitative Sciences, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| | - Marianne Matzo
- College of Family Medicine, Stephenson Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - George M Slavich
- Cousins Center for Psychoneuroimmunology, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
| | - Marc T Goodman
- Cancer Prevention and Genetics Program, Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - William Tew
- Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA
| | - Jenny Lester
- Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Kathleen M Moore
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - Beth Y Karlan
- Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Douglas A Levine
- Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Anil K Sood
- Department of Gynecologic Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA; Center for RNA Interference and Noncoding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
10
|
Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs 2017; 35:627-633. [PMID: 28283779 DOI: 10.1007/s10637-017-0444-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 02/20/2017] [Indexed: 01/01/2023]
Abstract
Background This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and preliminary efficacy of ME-344, a mitochondrial inhibitor, administered in combination with the topoisomerase I inhibitor, topotecan, in patients with previously treated, locally advanced or metastatic small cell lung (SCLC), ovarian and cervical cancers. Patients and methods In Part 1, patients received ME-344 10 mg/kg intravenously weekly on days 1, 8, 15 and 22 in combination with topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Cycles were repeated until disease progression or unacceptable toxicity. Patients were evaluated for dose-limiting toxicity (DLT) in cycle 1 and ME-344 pharmacokinetic samples were obtained. In Part 2, patients with locally advanced or metastatic SCLC and ovarian cancer were enrolled in expansion cohorts treated at the recommended phase II dose (RP2D) determined in Part 1. Results Fourteen patients were enrolled in Part 1 and no DLTs were observed. The RP2D of ME-344 in combination with topotecan was established as 10 mg/kg. In Part 2, 32 patients were enrolled. The most common treatment-emergent all-grade and grade 3/4 toxicities included fatigue (65.2%, 6.5%), neutropenia (56.5%, 43.5%) and thrombocytopenia (50%, 23.9%). One patient with recurrent ovarian cancer experienced a partial response by RECIST 1.1 and 21 patients achieved stable disease as best response. Conclusions The combination of ME-344 10 mg/kg weekly and topotecan 4 mg/m2 was tolerable, however, the degree of anti-cancer activity does not support further investigation of the combination in unselected patients with SCLC, ovarian and cervical cancers.
Collapse
Affiliation(s)
- Jennifer R Diamond
- University of Colorado Cancer Center, 12801 E. 17th Avenue, Mailstop 8117, Aurora, CO, 80045, USA.
| | - Barbara Goff
- University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA
| | | | - Johanna C Bendell
- Sara Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
| | | | | | | | | | | | - D Ross Camidge
- University of Colorado Cancer Center, 12801 E. 17th Avenue, Mailstop 8117, Aurora, CO, 80045, USA
| | - Erika Hamilton
- Sara Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
| | - Kathleen M Moore
- Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| |
Collapse
|
11
|
Lundqvist A, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Sanz LM, Liang S, Murray S, Larsson O, Kiessling R, Mao Y, Sidhom JW, Bessell CA, Havel J, Schneck J, Chan TA, Sachsenmeier E, Woods D, Berglund A, Ramakrishnan R, Sodre A, Weber J, Zappasodi R, Li Y, Qi J, Wong P, Sirard C, Postow M, Newman W, Koon H, Velcheti V, Callahan MK, Wolchok JD, Merghoub T, Lum LG, Choi M, Thakur A, Deol A, Dyson G, Shields A, Haymaker C, Uemura M, Murthy R, James M, Wang D, Brevard J, Monaghan C, Swann S, Geib J, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo J, Patel SP, Amaria R, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies MA, Hwu P, Overwijk WW, Bernatchez C, Diab A, Massarelli E, Segal NH, Ribrag V, Melero I, Gangadhar TC, Urba W, Schadendorf D, Ferris RL, Houot R, Morschhauser F, Logan T, Luke JJ, Sharfman W, Barlesi F, Ott PA, Mansi L, Kummar S, Salles G, Carpio C, Meier R, Krishnan S, McDonald D, Maurer M, Gu X, Neely J, Suryawanshi S, Levy R, Khushalani N, Wu J, Zhang J, Basher F, Rubinstein M, Bucsek M, Qiao G, Hembrough T, Spacek J, Vocka M, Zavadova E, Skalova H, Dundr P, Petruzelka L, Francis N, Tilman RT, Hartmann A, MacDonald C, Netikova I, Ballesteros-Merino C, Stump J, Tufman A, Berger F, Neuberger M, Hatz R, Lindner M, Sanborn RE, Handy J, Hylander B, Fox B, Bifulco C, Huber RM, Winter H, Reu S, Sun C, Xiao W, Tian Z, Arora K, Desai N, Repasky E, Kulkarni A, Rajurkar M, Rivera M, Deshpande V, Ting D, Tsai K, Nosrati A, Goldinger S, Hamid O, Algazi A, Chatterjee S, Tumeh P, Hwang J, Liu J, Chen L, Dummer R, Rosenblum M, Daud A, Tsao TS, Ashworth-Sharpe J, Johnson D, Daenthanasanmak A, Bhaumik S, Bieniarz C, Couto J, Farrell M, Ghaffari M, Habensus I, Hubbard A, Jones T, Kelly B, Kosmeder J, Chakraborty P, Lee C, Marner E, Meridew J, Polaske N, Racolta A, Uribe D, Zhang H, Zhang J, Zhang W, Zhu Y, Toth K, Morrison L, Pestic-Dragovich L, Tang L, Tsujikawa T, Borkar RN, Azimi V, Kumar S, Thibault G, Mori M, El Rassi E, Meek M, Clayburgh DR, Kulesz-Martin MF, Flint PW, Coussens LM, Villabona L, Masucci GV, Geiss G, Birditt B, Mei Q, Huang A, Garrett-Mayer E, White AM, Eagan MA, Ignacio E, Elliott N, Dunaway D, Dennis L, Warren S, Beechem J, Dunaway D, Jung J, Nishimura M, Merritt C, Sprague I, Webster P, Liang Y, Warren S, Beechem J, Wenthe J, Enblad G, Karlsson H, Essand M, Paulos C, Savoldo B, Dotti G, Höglund M, Brenner MK, Hagberg H, Loskog A, Bernett MJ, Moore GL, Hedvat M, Bonzon C, Beeson C, Chu S, Rashid R, Avery KN, Muchhal U, Desjarlais J, Hedvat M, Bernett MJ, Moore GL, Bonzon C, Rashid R, Yu X, Chu S, Avery KN, Muchhal U, Desjarlais J, Kraman M, Kmiecik K, Allen N, Faroudi M, Zimarino C, Wydro M, Mehrotra S, Doody J, Srinivasa SP, Govindappa N, Reddy P, Dubey A, Periyasamy S, Adekandi M, Dey C, Joy M, van Loo PF, Zhao F, Veninga H, Shamsili S, Throsby M, Dolstra H, Bakker L, Alva A, Gschwendt J, Loriot Y, Bellmunt J, Feng D, Evans K, Poehlein C, Powles T, Antonarakis ES, Drake CG, Wu H, Poehlein C, De Bono J, Bannerji R, Byrd J, Gregory G, Xiao C, Opat S, Shortt J, Yee AJ, Raje N, Thompson S, Balakumaran A, Kumar S, Rini BI, Choueiri TK, Mariani M, Holtzhausen A, Albiges L, Haanen JB, Atkins MB, Larkin J, Schmidinger M, Magazzù D, di Pietro A, Motzer RJ, Borch TH, Andersen R, Hanks BA, Kongsted P, Pedersen M, Nielsen M, Met Ö, Donia M, Svane IM, Boudadi K, Wang H, Vasselli J, Baughman JE, Scharping N, Wigginton J, Abdallah R, Ross A, Drake CG, Antonarakis ES, Canter RJ, Park J, Wang Z, Grossenbacher S, Luna JI, Menk AV, Withers S, Culp W, Chen M, Monjazeb A, Kent MS, Murphy WJ, Chandran S, Somerville R, Wunderlich J, Danforth D, Moreci R, Yang J, Sherry R, Klebanoff C, Goff S, Paria B, Sabesan A, Srivastava A, Rosenberg SA, Kammula U, Curti B, Whetstone R, Richards J, Faries M, Andtbacka RHI, Grose M, Shafren D, Diaz LA, Le DT, Yoshino T, André T, Bendell J, Dadey R, Koshiji M, Zhang Y, Kang SP, Lam B, Jäger D, Bauer TM, Wang JS, Lee JK, Manji GA, Kudchadkar R, Watkins S, Kauh JS, Tang S, Laing N, Falchook G, Garon EB, Halmos B, Rina H, Leighl N, Lee SS, Walsh W, Ferris R, Dragnev K, Piperdi B, Rodriguez LPA, Shinwari N, Wei Z, Gustafson MP, Maas ML, Deeds M, Armstrong A, Bornschlegl S, Delgoffe GM, Peterson T, Steinmetz S, Gastineau DA, Parney IF, Dietz AB, Herzog T, Backes FJ, Copeland L, Del Pilar Estevez Diz M, Hare TW, Peled J, Huh W, Kim BG, Moore KM, Oaknin A, Small W, Tewari KS, Monk BJ, Kamat AM, Bellmunt J, Choueiri TK, Devlin S, Nam K, De Santis M, Dreicer R, Hahn NM, Perini R, Siefker-Radtke A, Sonpavde G, de Wit R, Witjes JA, Keefe S, Staffas A, Bajorin D, Kline J, Armand P, Kuruvilla J, Moskowitz C, Hamadani M, Ribrag V, Zinzani PL, Chlosta S, Thompson S, Lumish M, Balakumaran A, Bartlett N, Kyi C, Sabado R, Saenger Y, William L, Donovan MJ, Sacris E, Mandeli J, Salazar AM, Rodriguez KP, Friedlander P, Bhardwaj N, Powderly J, Brody J, Nemunaitis J, Emens L, Luke JJ, Patnaik A, McCaffery I, Miller R, Ahr K, Laport G, Coveler AL, Smith DC, Grilley-Olson JE, Gajewski TF, Goel S, Gardai SJ, Law CL, Means G, Manley T, Perales M, Curti B, Marrone KA, Rosner G, Anagnostou V, Riemer J, Wakefield J, Zanhow C, Baylin S, Gitlitz B, Brahmer J, Giralt S, McDermott DF, Signoretti S, Li W, Schloss C, Michot JM, Armand P, Ding W, Ribrag V, Christian B, Balakumaran A, Taur Y, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani PL, Najjar YG, Lin, Butterfield LH, Tarhini AA, Davar D, Pamer E, Zarour H, Rush E, Sander C, Kirkwood JM, Fu S, Bauer T, Molineaux C, Bennett MK, Orford KW, Papadopoulos KP, van den Brink MRM, Padda SK, Shah SA, Colevas AD, Narayanan S, Fisher GA, Supan D, Wakelee HA, Aoki R, Pegram MD, Villalobos VM, Jenq R, Liu J, Takimoto CH, Chao M, Volkmer JP, Majeti R, Weissman IL, Sikic BI, Page D, Yu W, Conlin A, Annels N, Ruzich J, Lewis S, Acheson A, Kemmer K, Perlewitz K, Moxon NM, Mellinger S, Bifulco C, Martel M, Koguchi Y, Pandha H, Fox B, Urba W, McArthur H, Pedersen M, Westergaard MCW, Borch TH, Nielsen M, Kongsted P, Juhler-Nøttrup T, Donia M, Simpson G, Svane IM, Desai J, Markman B, Sandhu S, Gan H, Friedlander ML, Tran B, Meniawy T, Lundy J, Colyer D, Mostafid H, Ameratunga M, Norris C, Yang J, Li K, Wang L, Luo L, Qin Z, Mu S, Tan X, Song J, Harrington K, Millward M, Katz MHG, Bauer TW, Varadhachary GR, Acquavella N, Merchant N, Petroni G, Slingluff CL, Rahma OE, Rini BI, Melcher A, Powles T, Chen M, Song Y, Puhlmann M, Atkins MB, Sathyanaryanan S, Hirsch HA, Shu J, Deshpande A, Khattri A, Grose M, Reeves J, Zi T, Brisson R, Harvey C, Michaelson J, Law D, Seiwert T, Shah J, Mateos MV, Matsumoto M, Davies B, Blacklock H, Rocafiguera AO, Goldschmidt H, Iida S, Yehuda DB, Ocio E, Rodríguez-Otero P, Jagannath S, Lonial S, Kher U, Au G, Marinello P, San-Miguel J, Shah J, Lonial S, de Oliveira MR, Yimer H, Mateos MV, Rifkin R, Schjesvold F, Ocio E, Karpathy R, Rodríguez-Otero P, San-Miguel J, Ghori R, Marinello P, Jagannath S, Spreafico A, Lee V, Ngan RKC, To KF, Ahn MJ, Shafren D, Ng QS, Hong RL, Lin JC, Swaby RF, Gause C, Saraf S, Chan ATC, Lam E, Tannir NM, Meric-Bernstam F, Ricca J, Vaishampayan U, Orford KW, Molineaux C, Gross M, MacKinnon A, Whiting S, Voss M, Yu EY, Wu H, Schloss C, Merghoub T, Albertini MR, Ranheim EA, Hank JA, Zuleger C, McFarland T, Collins J, Clements E, Weber S, Weigel T, Neuman H, Wolchok JD, Hartig G, Mahvi D, Henry M, Gan J, Yang R, Carmichael L, Kim K, Gillies SD, Sondel PM, Subbiah V, Zamarin D, Murthy R, Noffsinger L, Hendricks K, Bosch M, Lee JM, Lee MH, Garon EB, Goldman JW, Baratelli FE, Schaue D, Batista L, Wang G, Rosen F, Yanagawa J, Walser TC, Lin YQ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Marliot F, Reckamp K, Wallace WD, Zeng G, Elashoff DA, Sharma S, Dubinett SM, Bhardwaj N, Friedlander P, Pavlick AC, Ernstoff MS, Vasaturo A, Gastman B, Hanks B, Albertini MR, Luke JJ, Keler T, Davis T, Vitale LA, Sharon E, Danaher P, Morishima C, Carpentier S, Cheever M, Fling S, Heery CR, Kim JW, Lamping E, Marte J, McMahon S, Cordes L, Fakhrejahani F, Madan R, Poggionovo C, Tsang K, Jochems C, Salazar R, Zhang M, Helwig C, Schlom J, Gulley JL, Li R, Amrhein J, Cohen Z, Frayssinet V, Champagne M, Kamat A, Aznar MA, Labiano S, Diaz-Lagares A, Esteller M, Sandoval J, Melero I, Barbee SD, Bellovin DI, Fieschi J, Timmer JC, Wondyfraw N, Johnson S, Park J, Chen A, Mkrtichyan M, Razai AS, Jones KS, Hata CY, Gonzalez D, Van den Eynde M, Deveraux Q, Eckelman BP, Borges L, Bhardwaj R, Puri RK, Suzuki A, Leland P, Joshi BH, Bartkowiak T, Jaiswal A, Pagès F, Ager C, Ai M, Budhani P, Chin R, Hong D, Curran M, Hastings WD, Pinzon-Ortiz M, Murakami M, Dobson JR, Galon J, Quinn D, Wagner JP, Rong X, Shaw P, Dammassa E, Guan W, Dranoff G, Cao A, Fulton RB, Leonardo S, Hermitte F, Fraser K, Kangas TO, Ottoson N, Bose N, Huhn RD, Graff J, Lowe J, Gorden K, Uhlik M, Vitale LA, Smith SG, O’Neill T, Widger J, Crocker A, He LZ, Weidlick J, Sundarapandiyan K, Ramakrishna V, Storey J, Thomas LJ, Goldstein J, Nguyen K, Marsh HC, Keler T, Grailer J, Gilden J, Stecha P, Garvin D, Hartnett J, Fan F, Cong M, Cheng ZJJ, Ravindranathan S, Hinner MJ, Aiba RSB, Schlosser C, Jaquin T, Allersdorfer A, Berger S, Wiedenmann A, Matschiner G, Schüler J, Moebius U, Koppolu B, Rothe C, Shane OA, Horton B, Spranger S, Gajewski TF, Moreira D, Adamus T, Zhao X, Swiderski P, Pal S, Zaharoff D, Kortylewski M, Kosmides A, Necochea K, Schneck J, Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Pham H, Hua P, Schvartsman G, Bu X, Zhu B, Hacohen N, Wu CJ, Fritsch E, Boussiotis VA, Freeman GJ, Moran AE, Polesso F, Lukaesko L, Bassett R, Weinberg A, Rådestad E, Egevad L, Mattsson J, Sundberg B, Henningsohn L, Levitsky V, Uhlin M, Rafelson W, Reagan JL, McQuade JL, Fast L, Sasikumar P, Sudarshan N, Ramachandra R, Gowda N, Samiulla D, Chandrasekhar T, Adurthi S, Mani J, Nair R, Haydu LE, Dhudashia A, Gowda N, Ramachandra M, Sankin A, Gartrell B, Cumberbatch K, Huang H, Stern J, Schoenberg M, Zang X, Davies MA, Swanson R, Kornacker M, Evans L, Rickel E, Wolfson M, Valsesia-Wittmann S, Shekarian T, Simard F, Nailo R, Dutour A, Tawbi H, Jallas AC, Caux C, Marabelle A, Glitza I, Kline D, Chen X, Fosco D, Kline J, Overacre A, Chikina M, Brunazzi E, Shayan G, Horne W, Kolls J, Ferris RL, Delgoffe GM, Bruno TC, Workman C, Vignali D, Adusumilli PS, Ansa-Addo EA, Li Z, Gerry A, Sanderson JP, Howe K, Docta R, Gao Q, Bagg EAL, Tribble N, Maroto M, Betts G, Bath N, Melchiori L, Lowther DE, Ramachandran I, Kari G, Basu S, Binder-Scholl G, Chagin K, Pandite L, Holdich T, Amado R, Zhang H, Glod J, Bernstein D, Jakobsen B, Mackall C, Wong R, Silk JD, Adams K, Hamilton G, Bennett AD, Brett S, Jing J, Quattrini A, Saini M, Wiedermann G, Gerry A, Jakobsen B, Binder-Scholl G, Brewer J, Duong M, Lu A, Chang P, Mahendravada A, Shinners N, Slawin K, Spencer DM, Foster AE, Bayle JH, Bergamaschi C, Ng SSM, Nagy B, Jensen S, Hu X, Alicea C, Fox B, Felber B, Pavlakis G, Chacon J, Yamamoto T, Garrabrant T, Cortina L, Powell DJ, Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Dolton G, Szomolay B, Ott S, Lyngaa R, Hadrup SR, Sewell AK, Svane IM, Fan A, Kumai T, Celis E, Frank I, Stramer A, Blaskovich MA, Wardell S, Fardis M, Bender J, Lotze MT, Goff SL, Zacharakis N, Assadipour Y, Prickett TD, Gartner JJ, Somerville R, Black M, Xu H, Chinnasamy H, Kriley I, Lu L, Wunderlich J, Robbins PF, Rosenberg S, Feldman SA, Trebska-McGowan K, Kriley I, Malekzadeh P, Payabyab E, Sherry R, Rosenberg S, Goff SL, Gokuldass A, Blaskovich MA, Kopits C, Rabinovich B, Lotze MT, Green DS, Kamenyeva O, Zoon KC, Annunziata CM, Hammill J, Helsen C, Aarts C, Bramson J, Harada Y, Yonemitsu Y, Helsen C, Hammill J, Mwawasi K, Denisova G, Bramson J, Giri R, Jin B, Campbell T, Draper LM, Stevanovic S, Yu Z, Weissbrich B, Restifo NP, Trimble CL, Rosenberg S, Hinrichs CS, Tsang K, Fantini M, Hodge JW, Fujii R, Fernando I, Jochems C, Heery C, Gulley J, Soon-Shiong P, Schlom J, Jing W, Gershan J, Blitzer G, Weber J, McOlash L, Johnson BD, Kiany S, Gangxiong H, Kleinerman ES, Klichinsky M, Ruella M, Shestova O, Kenderian S, Kim M, Scholler J, June CH, Gill S, Moogk D, Zhong S, Yu Z, Liadi I, Rittase W, Fang V, Dougherty J, Perez-Garcia A, Osman I, Zhu C, Varadarajan N, Restifo NP, Frey A, Krogsgaard M, Landi D, Fousek K, Mukherjee M, Shree A, Joseph S, Bielamowicz K, Byrd T, Ahmed N, Hegde M, Lee S, Byrd D, Thompson J, Bhatia S, Tykodi S, Delismon J, Chu L, Abdul-Alim S, Ohanian A, DeVito AM, Riddell S, Margolin K, Magalhaes I, Mattsson J, Uhlin M, Nemoto S, Villarroel PP, Nakagawa R, Mule JJ, Mailloux AW, Mata M, Nguyen P, Gerken C, DeRenzo C, Spencer DM, Gottschalk S, Mathieu M, Pelletier S, Stagg J, Turcotte S, Minutolo N, Sharma P, Tsourkas A, Powell DJ, Mockel-Tenbrinck N, Mauer D, Drechsel K, Barth C, Freese K, Kolrep U, Schult S, Assenmacher M, Kaiser A, Mullinax J, Hall M, Le J, Kodumudi K, Royster E, Richards A, Gonzalez R, Sarnaik A, Pilon-Thomas S, Nielsen M, Krarup-Hansen A, Hovgaard D, Petersen MM, Loya AC, Junker N, Svane IM, Rivas C, Parihar R, Gottschalk S, Rooney CM, Qin H, Nguyen S, Su P, Burk C, Duncan B, Kim BH, Kohler ME, Fry T, Rao AA, Teyssier N, Pfeil J, Sgourakis N, Salama S, Haussler D, Richman SA, Nunez-Cruz S, Gershenson Z, Mourelatos Z, Barrett D, Grupp S, Milone M, Rodriguez-Garcia A, Robinson MK, Adams GP, Powell DJ, Santos J, Havunen R, Siurala M, Cervera-Carrascón V, Parviainen S, Antilla M, Hemminki A, Sethuraman J, Santiago L, Chen JQ, Dai Z, Wardell S, Bender J, Lotze MT, Sha H, Su S, Ding N, Liu B, Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA, Hinrichs CS, Bhatia S, Burgess M, Zhang H, Lee T, Klingemann H, Soon-Shiong P, Nghiem P, Kirkwood JM, Rossi JM, Sherman M, Xue A, Shen YW, Navale L, Rosenberg SA, Kochenderfer JN, Bot A, Veerapathran A, Gokuldass A, Stramer A, Sethuraman J, Blaskovich MA, Wiener D, Frank I, Santiago L, Rabinovich B, Fardis M, Bender J, Lotze MT, Waller EK, Li JM, Petersen C, Blazar BR, Li J, Giver CR, Wang Z, Grossenbacher SK, Sturgill I, Canter RJ, Murphy WJ, Zhang C, Burger MC, Jennewein L, Waldmann A, Mittelbronn M, Tonn T, Steinbach JP, Wels WS, Williams JB, Zha Y, Gajewski TF, Williams LC, Krenciute G, Kalra M, Louis C, Gottschalk S, Xin G, Schauder D, Jiang A, Joshi N, Cui W, Zeng X, Menk AV, Scharping N, Delgoffe GM, Zhao Z, Hamieh M, Eyquem J, Gunset G, Bander N, Sadelain M, Askmyr D, Abolhalaj M, Lundberg K, Greiff L, Lindstedt M, Angell HK, Kim KM, Kim ST, Kim S, Sharpe AD, Ogden J, Davenport A, Hodgson DR, Barrett C, Lee J, Kilgour E, Hanson J, Caspell R, Karulin A, Lehmann P, Ansari T, Schiller A, Sundararaman S, Lehmann P, Hanson J, Roen D, Karulin A, Lehmann P, Ayers M, Levitan D, Arreaza G, Liu F, Mogg R, Bang YJ, O’Neil B, Cristescu R, Friedlander P, Wassman K, Kyi C, Oh W, Bhardwaj N, Bornschlegl S, Gustafson MP, Gastineau DA, Parney IF, Dietz AB, Carvajal-Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D, Chang S, Levy R, Kurland J, Krishnan S, Ahlers CM, Jure-Kunkel M, Cohen L, Maecker H, Kohrt H, Chen S, Crabill G, Pritchard T, McMiller T, Pardoll D, Pan F, Topalian S, Danaher P, Warren S, Dennis L, White AM, D’Amico L, Geller M, Disis ML, Beechem J, Odunsi K, Fling S, Derakhshandeh R, Webb TJ, Dubois S, Conlon K, Bryant B, Hsu J, Beltran N, Müller J, Waldmann T, Duhen R, Duhen T, Thompson L, Montler R, Weinberg A, Kates M, Early B, Yusko E, Schreiber TH, Bivalacqua TJ, Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng J, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert T, Ribas A, McClanahan TK, Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Nebozhyn M, Lunceford J, Joe A, Cheng J, Plimack E, Ott PA, McClanahan TK, Loboda A, Kaufman DR, Forrest-Hay A, Guyre CA, Narumiya K, Delcommenne M, Hirsch HA, Deshpande A, Reeves J, Shu J, Zi T, Michaelson J, Law D, Trehu E, Sathyanaryanan S, Hodkinson BP, Hutnick NA, Schaffer ME, Gormley M, Hulett T, Jensen S, Ballesteros-Merino C, Dubay C, Afentoulis M, Reddy A, David L, Fox B, Jayant K, Agrawal S, Agrawal R, Jeyakumar G, Kim S, Kim H, Silski C, Suisham S, Heath E, Vaishampayan U, Vandeven N, Viller NN, O’Connor A, Chen H, Bossen B, Sievers E, Uger R, Nghiem P, Johnson L, Kao HF, Hsiao CF, Lai SC, Wang CW, Ko JY, Lou PJ, Lee TJ, Liu TW, Hong RL, Kearney SJ, Black JC, Landis BJ, Koegler S, Hirsch B, Gianani R, Kim J, He MX, Zhang B, Su N, Luo Y, Ma XJ, Park E, Kim DW, Copploa D, Kothari N, doo Chang Y, Kim R, Kim N, Lye M, Wan E, Kim N, Lye M, Wan E, Kim N, Lye M, Wan E, Knaus HA, Berglund S, Hackl H, Karp JE, Gojo I, Luznik L, Hong HS, Koch SD, Scheel B, Gnad-Vogt U, Kallen KJ, Wiegand V, Backert L, Kohlbacher O, Hoerr I, Fotin-Mleczek M, Billingsley JM, Koguchi Y, Conrad V, Miller W, Gonzalez I, Poplonski T, Meeuwsen T, Howells-Ferreira A, Rattray R, Campbell M, Bifulco C, Dubay C, Bahjat K, Curti B, Urba W, Vetsika EK, Kallergi G, Aggouraki D, Lyristi Z, Katsarlinos P, Koinis F, Georgoulias V, Kotsakis A, Martin NT, Aeffner F, Kearney SJ, Black JC, Cerkovnik L, Pratte L, Kim R, Hirsch B, Krueger J, Gianani R, Martínez-Usatorre A, Jandus C, Donda A, Carretero-Iglesia L, Speiser DE, Zehn D, Rufer N, Romero P, Panda A, Mehnert J, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Sokol L, Stein M, Poplin E, Rodriguez-Rodriguez L, Silk A, Chan N, Frankel M, Kane M, Malhotra J, Aisner J, Kaufman HL, Ali S, Ross J, White E, Bhanot G, Ganesan S, Monette A, Bergeron D, Amor AB, Meunier L, Caron C, Morou A, Kaufmann D, Liberman M, Jurisica I, Mes-Masson AM, Hamzaoui K, Lapointe R, Mongan A, Ku YC, Tom W, Sun Y, Pankov A, Looney T, Au-Young J, Hyland F, Conroy J, Morrison C, Glenn S, Burgher B, Ji H, Gardner M, Mongan A, Omilian AR, Conroy J, Bshara W, Angela O, Burgher B, Ji H, Glenn S, Morrison C, Mongan A, Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL, Obeid JM, Erdag G, Deacon DH, Slingluff CL, Bullock TN, Loffredo JT, Vuyyuru R, Beyer S, Spires VM, Fox M, Ehrmann JM, Taylor KA, Korman AJ, Graziano RF, Page D, Sanchez K, Ballesteros-Merino C, Martel M, Bifulco C, Urba W, Fox B, Patel SP, De Macedo MP, Qin Y, Reuben A, Spencer C, Guindani M, Bassett R, Wargo J, Racolta A, Kelly B, Jones T, Polaske N, Theiss N, Robida M, Meridew J, Habensus I, Zhang L, Pestic-Dragovich L, Tang L, Sullivan RJ, Logan T, Khushalani N, Margolin K, Koon H, Olencki T, Hutson T, Curti B, Roder J, Blackmon S, Roder H, Stewart J, Amin A, Ernstoff MS, Clark JI, Atkins MB, Kaufman HL, Sosman J, Weber J, McDermott DF, Weber J, Kluger H, Halaban R, Snzol M, Roder H, Roder J, Asmellash S, Steingrimsson A, Blackmon S, Sullivan RJ, Wang C, Roman K, Clement A, Downing S, Hoyt C, Harder N, Schmidt G, Schoenmeyer R, Brieu N, Yigitsoy M, Madonna G, Botti G, Grimaldi A, Ascierto PA, Huss R, Athelogou M, Hessel H, Harder N, Buchner A, Schmidt G, Stief C, Huss R, Binnig G, Kirchner T, Sellappan S, Thyparambil S, Schwartz S, Cecchi F, Nguyen A, Vaske C. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. J Immunother Cancer 2016. [PMCID: PMC5123387 DOI: 10.1186/s40425-016-0172-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
12
|
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, Arnoux T, Chanuc F, Fuseri N, Wilkinson RW, Wagtmann N, Morel Y, Andre P, Atkins MB, Carlino MS, Ribas A, Thompson JA, Choueiri TK, Hodi FS, Hwu WJ, McDermott DF, Atkinson V, Cebon JS, Fitzharris B, Jameson MB, McNeil C, Hill AG, Mangin E, Ahamadi M, van Vugt M, van Zutphen M, Ibrahim N, Long GV, Gartrell R, Blake Z, Simoes I, Fu Y, Saito T, Qian Y, Lu Y, Saenger YM, Budhu S, De Henau O, Zappasodi R, Schlunegger K, Freimark B, Hutchins J, Barker CA, Wolchok JD, Merghoub T, Burova E, Allbritton O, Hong P, Dai J, Pei J, Liu M, Kantrowitz J, Lai V, Poueymirou W, MacDonald D, Ioffe E, Mohrs M, Olson W, Thurston G, Capasso C, Frascaro F, Carpi S, Tähtinen S, Feola S, Fusciello M, Peltonen K, Martins B, Sjöberg M, Pesonen S, Ranki T, Kyruk L, Ylösmäki E, Cerullo V, Cerignoli F, Xi B, Guenther G, Yu N, Muir L, Zhao L, Abassi Y, Cervera-Carrascón V, Siurala M, Santos J, Havunen R, Parviainen S, Hemminki A, Alemany R, Loskog A, Jhawar S, Goyal S, Bommareddy PK, Paneque T, Kaufman HL, Zloza A, Kaufman HL, Silk A, Dalgleish A, Mehnert J, Gabrail N, Bryan J, Medina D, Bommareddy PK, Shafren D, Grose M, Zloza A, Mitchell L, Yagiz K, Mudan S, Lopez F, Mendoza D, Munday A, Gruber H, Jolly D, Fuhrmann S, Radoja S, Tan W, Pourchet A, Frey A, DeBenedette M, Mohr I, Mulvey M, Ranki T, Pesonen S, Capasso C, Ylösmäki E, Cerullo V, Andtbacka RHI, Ross M, Agarwala S, Plachco A, Grossmann K, Taylor M, Vetto J, Neves R, Daud A, Khong H, Meek SM, Ungerleider R, Welden S, Tanaka M, Gamble A, Williams M, Andtbacka RHI, Curti B, Hallmeyer S, Fox B, Feng Z, Paustian C, Bifulco C, Grose M, Shafren D, Grogan EW, Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Krisko J, Hemmi S, de Gruijl T, Kanerva A, Hemminki A, Ansari T, Sundararaman S, Roen D, Lehmann P, Bloom AC, Bender LH, Tcherepanova I, Walters IB, Terabe M, Berzofsky JA, Chapelin F, Okada H, Ahrens ET, DeFalco J, Harbell M, Manning-Bog A, Scholz A, Nicolette C, Zhang D, Baia G, Tan YC, Sokolove J, Kim D, Williamson K, Chen X, Colrain J, Santo GE, Nguyen N, Dhupkar P, Volkmuth W, Greenberg N, Robinson W, Emerling D, Drake CG, Petrylak DP, Antonarakis ES, Kibel AS, Chang NN, Vu T, Yu L, Campogan D, Haynes H, Trager JB, Sheikh NA, Quinn DI, Kirk P, Addepalli M, Chang T, Zhang P, Konakova M, Kleinerman ES, Hagihara K, Pai S, VanderVeen L, Obalapur P, Kuo P, Quach P, Fong L, Charych DH, Zalevsky J, Langowski JL, Gordon N, Addepalli M, Kirksey Y, Nutakki R, Kolarkar S, Pena R, Hoch U, Zalevsky J, Doberstein SK, Charych DH, Cha J, Grenga I, Mallon Z, Perez M, McDaniel A, Anand S, Uecker D, Nuccitelli R, McDaniel A, Anand S, Cha J, Uecker D, Lepone L, Nuccitelli R, Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett D, Kalinski P, Renrick AN, Thounaojam M, Gameiro S, Thomas P, Pellom S, Shanker A, Pellom S, Thounaojam M, Dudimah D, Brooks A, Sayers TJ, Shanker A, Su YL, Knudson KM, Adamus T, Zhang Q, Nechaev S, Kortylewski M, Wei S, Allison J, Anderson C, Tang C, Schoenhals J, Tsouko E, Fantini M, Heymach J, de Groot P, Chang J, Hess KR, Diab A, Sharma P, Allison J, Naing A, Hong D, Welsh J, Tsang K, Albershardt TC, Parsons AJ, Leleux J, Reeves RS, ter Meulen J, Berglund P, Ascarateil S, Koziol ME, Penny SA, Malaker SA, Hodge J, Steadman L, Myers PT, Bai D, Shabanowitz J, Hunt DF, Cobbold M, Dai P, Wang W, Yang N, Shuman S, Donahue R, Merghoub T, Wolchok JD, Deng L, Dillon P, Petroni G, Brenin D, Bullock K, Olson W, Smolkin ME, Smith K, Schlom J, Nail C, Slingluff CL, Sharma M, Fa’ak F, Janssen L, Khong H, Xiao Z, Hailemichael Y, Singh M, Vianden C, Evans E, Diab A, Zalevsky J, Hoch U, Overwijk WW, Facciabene A, Stefano P, Chongyung F, Rafail S, Hailemichael Y, Nielsen M, Bussler H, Fa’ak F, Vanderslice P, Woodside DG, Market RV, Biediger RJ, Marathi UK, Overwijk WW, Hollevoet K, Geukens N, Declerck P, Mallow C, Joly N, McIntosh L, Paramithiotis E, Rizell M, Sternby M, Andersson B, Karlsson-Parra A, Kuai R, Ochyl L, Schwendeman A, Reilly C, Moon J, Deng W, Hudson TE, Lemmens EE, Hanson B, Rae CS, Burrill J, Skoble J, Katibah G, Murphy AL, Torno S, deVries M, Brockstedt DG, Leong ML, Lauer P, Dubensky TW, Whiting CC, Chen X, Hu Y, Xia Y, Zhou L, Scrivens M, Bao Y, Huang S, Ren X, Hurt E, Hollingsworth RE, Chang AE, Wicha MS, Li Q, Aggarwal C, Mangrolia D, Foster C, Cohen R, Weinstein G, Morrow M, Bauml J, Kraynyak K, Boyer J, Yan J, Lee J, Humeau L, Oyola S, Howell A, Duff S, Weiner D, Yang Z, Bagarazzi M, McNeel DG, Eickhoff J, Jeraj R, Staab MJ, Straus J, Rekoske B, Balch L, Liu G, Melssen M, Petroni G, Grosh W, Varhegyi N, Bullock K, Smolkin ME, Smith K, Galeassi N, Deacon DH, Knapp A, Gaughan E, Slingluff CL, Ghisoli M, Barve M, Mennel R, Wallraven G, Manning L, Senzer N, Nemunaitis J, Ogasawara M, Leonard JE, Ota S, Peace KM, Hale DF, Vreeland TJ, Jackson DO, Berry JS, Trappey AF, Herbert GS, Clifton GT, Hardin MO, Paris M, Toms A, Qiao N, Litton J, Peoples GE, Mittendorf EA, Ghamsari L, Flano E, Jacques J, Liu B, Havel J, Fisher T, Makarov V, Merghoub T, Wolchok JD, Hellmann MD, Chan TA, Flechtner JB, Stefano P, Facciabene A, Facciponte J, Ugel S, Hu-Lieskovan S, De Sanctis F, Coukos G, Paris S, Pottier A, Levy L, Lu B, Cappuccini F, Pollock E, Bryant R, Hamdy F, Ribas A, Hill A, Redchenko I, Sultan H, Kumai T, Fesenkova V, Celis E, Tsang K, Fantini M, Fernando I, Palena C, Smith E, David JM, Hodge J, Gabitzsch E, Jones F, Gulley JL, Schlom J, Herranz MU, Rafail S, Ugel S, Facciponte J, Zauderer M, Stefano P, Facciabene A, Wada H, Shimizu A, Osada T, Fukaya S, Sasaki E, Abolhalaj M, Askmyr D, Lundberg K, Fogler W, Albrekt AS, Greiff L, Lindstedt M, Flies DB, Higuchi T, Ornatowski W, Harris J, Adams SF, Aguilera T, Rafat M, Franklin M, Castellini L, Shehade H, Kariolis M, Jang D, vonEbyen R, Graves E, Ellies L, Rankin E, Koong A, Giaccia A, Thayer M, Ajina R, Wang S, Smith J, Pierobon M, Jablonski S, Petricoin E, Weiner LM, Sherry L, Waller J, Anderson M, Saims D, Bigley A, Bernatchez C, Haymaker C, Tannir NM, Kluger H, Tetzlaff M, Jackson N, Gergel I, Tagliaferri M, Zalevsky J, Magnani JL, Hoch U, Hwu P, Snzol M, Hurwitz M, Diab A, Barberi T, Martin A, Suresh R, Barakat D, Harris-Bookman S, Gong J, Drake C, Friedman A, Berkey S, Downs-Canner S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett D, Obermajer N, Gray M, Bruno TC, Moore B, Squalls O, Ebner P, Waugh K, Mitchell J, Franklin W, Merrick D, McCarter M, Palmer B, Hutchins J, Kern J, Vignali D, Slansky J, Chan ASH, Qiu X, Fraser K, Jonas A, Ottoson N, Gordon K, Kangas TO, Freimark B, Leonardo S, Ertelt K, Walsh R, Uhlik M, Graff J, Bose N, Gupta R, Mandloi N, Paul K, Patil A, Fromm G, Sathian R, Mohan A, Manoharan M, Chaudhuri A, Chen Y, Lin J, Ye YB, Xu CW, Chen G, Guo ZQ, de Silva S, Komarov A, Chenchik A, Makhanov M, Frangou C, Zheng Y, Coltharp C, Unfricht D, Dilworth R, Fridman L, Liu L, Giffin L, Rajopadhye M, Miller P, Concha-Benavente F, Bauman J, Trivedi S, Srivastava R, Ohr J, Heron D, Duvvuri U, Kim S, Xu X, Gooding W, Ferris RL, Torrey H, Mera T, Okubo Y, Vanamee E, Foster R, Faustman D, Gartrell R, Stack E, Rose J, Lu Y, Izaki D, Beck K, Jia DT, Armenta P, White-Stern A, Fu Y, Blake Z, Marks D, Kaufman HL, Schreiber TH, Taback B, Horst B, Saenger YM, Glickman LH, Kanne DB, Gauthier KS, Desbien AL, Francica B, Katibah G, Corrales LP, Fantini M, Leong JL, Sung L, Metchette K, Kasibhatla S, Pferdekamper AM, Zheng L, Cho C, Feng Y, McKenna JM, Tallarico J, Gameiro SR, Bender S, Ndubaku C, McWhirter SM, Drake CG, Gajewski TF, Dubensky TW, Gugel EG, Bell CJM, Munk A, Muniz L, Knudson KM, Bhardwaj N, Zhao F, Evans K, Xiao C, Holtzhausen A, Hanks BA, Scholler N, Yin C, Van der Meijs P, Prantner AM, Clavijo PE, Krejsa CM, Smith L, Johnson B, Branstetter D, Stein PL, Jaen JC, Tan JBL, Chen A, Chen Y, Park T, Allen CT, Powers JP, Sexton H, Xu G, Young SW, Schindler U, Deng W, Klinke DJ, Komar HM, Mace T, Serpa G, Donahue R, Elnaggar O, Conwell D, Hart P, Schmidt C, Dillhoff M, Jin M, Ostrowski MC, Lesinski GB, Koti M, Au K, Lepone L, Peterson N, Truesdell P, Reid-Schachter G, Graham C, Craig A, Francis JA, Kotlan B, Balatoni T, Farkas E, Toth L, Grenga I, Ujhelyi M, Savolt A, Doleschall Z, Horvath S, Eles K, Olasz J, Csuka O, Kasler M, Liszkay G, Barnea E, Hodge JW, Kumar S, Tsujikawa T, Blakely C, Flynn P, Goodman R, Bueno R, Sugarbaker D, Jablons D, Broaddus VC, West B, Tsang KY, Coussens LM, Kunk PR, Obeid JM, Winters K, Pramoonjago P, Smolkin ME, Stelow EB, Bauer TW, Slingluff CL, Rahma OE, Schlom J, Lamble A, Kosaka Y, Huang F, Saser KA, Adams H, Tognon CE, Laderas T, McWeeney S, Loriaux M, Tyner JW, Gray M, Druker BJ, Lind EF, Liu Z, Lu S, Kane LP, Ferris RL, Liu Z, Shayan G, Lu S, Ferris RL, Gong J, Femel J, Tsujikawa T, Lane R, Booth J, Lund AW, Melssen M, Rodriguez A, Slingluff CL, Engelhard VH, Metelli A, Hutchins J, Wu BX, Fugle CW, Saleh R, Sun S, Wu J, Liu B, Li Z, Morris ZS, Guy EI, Heinze C, Freimark B, Kler J, Gressett MM, Werner LR, Gillies SD, Korman AJ, Loibner H, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM, Grogan J, Newman J, Zloza A, Huelsmann E, Broucek J, Kaufman HL, Brech D, Straub T, Irmler M, Beckers J, Buettner F, Manieri N, Schaeffeler E, Schwab M, Noessner E, Anand S, McDaniel A, Cha J, Uecker D, Nuccitelli R, Ordentlich P, Wolfreys A, Chiang E, Da Costa A, Silva J, Crosby A, Staelens L, Craggs G, Cauvin A, Mason S, Paterson AM, Lake AC, Armet CM, Caplazi P, O’Connor RW, Hill JA, Normant E, Adam A, Biniszkiewicz DM, Chappel SC, Palombella VJ, Holland PM, Powers JP, Becker A, Yadav M, Chen A, Leleti MR, Newcomb E, Sexton H, Schindler U, Tan JBL, Young SW, Jaen JC, Rapisuwon S, Radfar A, Hagner P, Gardner K, Gibney G, Atkins M, Rennier KR, Crowder R, Wang P, Pachynski RK, Carrero RMS, Rivas S, Beceren-Braun F, Chiu H, Anthony S, Schluns KS, Sawant D, Chikina M, Yano H, Workman C, Vignali D, Salerno E, Bedognetti D, Mauldin I, Waldman M, Deacon D, Shea S, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski T, Marincola FM, Slingluff CL, Spranger S, Klippel A, Horton B, Gajewski TF, Suzuki A, Leland P, Joshi BH, Puri RK, Sweis RF, Bao R, Luke J, Gajewski TF, Thakurta A, Theodoraki MN, Mogundo FM, Edwards RP, Kalinski P, Won H, Moreira D, Gao C, Zhao X, Duttagupta P, Jones J, Pourdehnad M, D’Apuzzo M, Pal S, Kortylewski M, Gandhi A, Henrich I, Quick L, Young R, Chou M, Hotson A, Willingham S, Ho P, Choy C, Laport G, McCaffery I, Miller R, Tipton KA, Wong KR, Singson V, Wong C, Chan C, Huang Y, Liu S, Richardson JH, Kavanaugh WM, West J, Irving BA, Tipton KA, Wong KR, Singson V, Wong C, Chan C, Huang Y, Liu S, Richardson JH, Kavanaugh WM, West J, Irving BA, Jaini R, Loya M, Eng C, Johnson ML, Adjei AA, Opyrchal M, Ramalingam S, Janne PA, Dominguez G, Gabrilovich D, de Leon L, Hasapidis J, Diede SJ, Ordentlich P, Cruickshank S, Meyers ML, Hellmann MD, Kalinski P, Zureikat A, Edwards R, Muthuswamy R, Obermajer N, Urban J, Butterfield LH, Gooding W, Zeh H, Bartlett D, Zubkova O, Agapova L, Kapralova M, Krasovskaia L, Ovsepyan A, Lykov M, Eremeev A, Bokovanov V, Grigoryeva O, Karpov A, Ruchko S, Nicolette C, Shuster A, Khalil DN, Campesato LF, Li Y, Merghoub T, Wolchok JD, Lazorchak AS, Patterson TD, Ding Y, Sasikumar P, Sudarshan N, Gowda N, Ramachandra R, Samiulla D, Giri S, Eswarappa R, Ramachandra M, Tuck D, Wyant T, Leshem J, Liu XF, Bera T, Terabe M, Bossenmaier B, Niederfellner G, Reiter Y, Pastan I, Xia L, Xia Y, Hu Y, Wang Y, Bao Y, Dai F, Huang S, Hurt E, Hollingsworth RE, Lum LG, Chang AE, Wicha MS, Li Q, Mace T, Makhijani N, Talbert E, Young G, Guttridge D, Conwell D, Lesinski GB, Gonzales RJMM, Huffman AP, Wang XK, Reshef R, MacKinnon A, Chen J, Gross M, Marguier G, Shwonek P, Sotirovska N, Steggerda S, Parlati F, Makkouk A, Bennett MK, Chen J, Emberley E, Gross M, Huang T, Li W, MacKinnon A, Marguier G, Neou S, Pan A, Zhang J, Zhang W, Parlati F, Marshall N, Marron TU, Agudo J, Brown B, Brody J, McQuinn C, Mace T, Farren M, Komar H, Shakya R, Young G, Ludwug T, Lesinski GB, Morillon YM, Hammond SA, Schlom J, Greiner JW, Nath PR, Schwartz AL, Maric D, Roberts DD, Obermajer N, Bartlett D, Kalinski P, Naing A, Papadopoulos KP, Autio KA, Wong DJ, Patel M, Falchook G, Pant S, Ott PA, Whiteside M, Patnaik A, Mumm J, Janku F, Chan I, Bauer T, Colen R, VanVlasselaer P, Brown GL, Tannir NM, Oft M, Infante J, Lipson E, Gopal A, Neelapu SS, Armand P, Spurgeon S, Leonard JP, Hodi FS, Sanborn RE, Melero I, Gajewski TF, Maurer M, Perna S, Gutierrez AA, Clynes R, Mitra P, Suryawanshi S, Gladstone D, Callahan MK, Crooks J, Brown S, Gauthier A, de Boisferon MH, MacDonald A, Brunet LR, Rothwell WT, Bell P, Wilson JM, Sato-Kaneko F, Yao S, Zhang SS, Carson DA, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Hayashi T, Cohen EEW, Schaer D, Li Y, Dobkin J, Amatulli M, Hall G, Doman T, Manro J, Dorsey FC, Sams L, Holmgaard R, Persaud K, Ludwig D, Surguladze D, Kauh JS, Novosiadly R, Kalos M, Driscoll K, Pandha H, Ralph C, Harrington K, Curti B, Sanborn RE, Akerley W, Gupta S, Melcher A, Mansfield D, Kaufman DR, Schmidt E, Grose M, Davies B, Karpathy R, Shafren D, Shamalov K, Cohen C, Sharma N, Allison J, Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A, Slomovitz BM, Moore KM, Youssoufian H, Posner M, Tewary P, Brooks AD, Xu YM, Wijeratne K, Gunatilaka LAA, Sayers TJ, Vasilakos JP, Alston T, Dovedi S, Elvecrog J, Grigsby I, Herbst R, Johnson K, Moeckly C, Mullins S, Siebenaler K, SternJohn J, Tilahun A, Tomai MA, Vogel K, Wilkinson RW, Vietsch EE, Wellstein A, Wythes M, Crosignani S, Tumang J, Alekar S, Bingham P, Cauwenberghs S, Chaplin J, Dalvie D, Denies S, De Maeseneire C, Feng J, Frederix K, Greasley S, Guo J, Hardwick J, Kaiser S, Jessen K, Kindt E, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Murray B, Pirson R, Preillon J, Rabolli V, Ray C, Ryan K, Scales S, Srirangam J, Solowiej J, Stewart A, Streiner N, Torti V, Tsaparikos K, Zheng X, Driessens G, Gomes B, Kraus M, Xu C, Zhang Y, Kradjian G, Qin G, Qi J, Xu X, Marelli B, Yu H, Guzman W, Tighe R, Salazar R, Lo KM, English J, Radvanyi L, Lan Y, Zappasodi R, Budhu S, Hellmann MD, Postow M, Senbabaoglu Y, Gasmi B, Zhong H, Li Y, Liu C, Hirschhorhn-Cymerman D, Wolchok JD, Merghoub T, Zha Y, Malnassy G, Fulton N, Park JH, Stock W, Nakamura Y, Gajewski TF, Liu H, Ju X, Kosoff R, Ramos K, Coder B, Petit R, Princiotta M, Perry K, Zou J, Arina A, Fernandez C, Zheng W, Beckett MA, Mauceri HJ, Fu YX, Weichselbaum RR, DeBenedette M, Lewis W, Gamble A, Nicolette C, Han Y, Wu Y, Yang C, Huang J, Wu D, Li J, Liang X, Zhou X, Hou J, Hassan R, Jahan T, Antonia SJ, Kindler HL, Alley EW, Honarmand S, Liu W, Leong ML, Whiting CC, Nair N, Enstrom A, Lemmens EE, Tsujikawa T, Kumar S, Coussens LM, Murphy AL, Brockstedt DG, Koch SD, Sebastian M, Weiss C, Früh M, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geissler M, Griesinger F, Kollmeier J, Papachristofilou A, Doener F, Fotin-Mleczek M, Hipp M, Hong HS, Kallen KJ, Klinkhardt U, Stosnach C, Scheel B, Schroeder A, Seibel T, Gnad-Vogt U, Zippelius A, Park HR, Ahn YO, Kim TM, Kim S, Kim S, Lee YS, Keam B, Kim DW, Heo DS, Pilon-Thomas S, Weber A, Morse J, Kodumudi K, Liu H, Mullinax J, Sarnaik AA, Pike L, Bang A, Ott PA, Balboni T, Taylor A, Spektor A, Wilhite T, Krishnan M, Cagney D, Alexander B, Aizer A, Buchbinder E, Awad M, Ghandi L, Hodi FS, Schoenfeld J, Schwartz AL, Nath PR, Lessey-Morillon E, Ridnour L, Roberts DD, Segal NH, Sharma M, Le DT, Ott PA, Ferris RL, Zelenetz AD, Neelapu SS, Levy R, Lossos IS, Jacobson C, Ramchandren R, Godwin J, Colevas AD, Meier R, Krishnan S, Gu X, Neely J, Suryawanshi S, Timmerman J, Vanpouille-Box CI, Formenti SC, Demaria S, Wennerberg E, Mediero A, Cronstein BN, Formenti SC, Demaria S, Gustafson MP, DiCostanzo A, Wheatley C, Kim CH, Bornschlegl S, Gastineau DA, Johnson BD, Dietz AB, MacDonald C, Bucsek M, Qiao G, Hylander B, Repasky E, Turbitt WJ, Xu Y, Mastro A, Rogers CJ, Withers S, Wang Z, Khuat LT, Dunai C, Blazar BR, Longo D, Rebhun R, Grossenbacher SK, Monjazeb A, Murphy WJ, Rowlinson S, Agnello G, Alters S, Lowe D, Scharping N, Menk AV, Whetstone R, Zeng X, Delgoffe GM, Santos PM, Menk AV, Shi J, Delgoffe GM, Butterfield LH, Whetstone R, Menk AV, Scharping N, Delgoffe G, Nagasaka M, Sukari A, Byrne-Steele M, Pan W, Hou X, Brown B, Eisenhower M, Han J, Collins N, Manguso R, Pope H, Shrestha Y, Boehm J, Haining WN, Cron KR, Sivan A, Aquino-Michaels K, Gajewski TF, Orecchioni M, Bedognetti D, Hendrickx W, Fuoco C, Spada F, Sgarrella F, Cesareni G, Marincola F, Kostarelos K, Bianco A, Delogu L, Hendrickx W, Roelands J, Boughorbel S, Decock J, Presnell S, Wang E, Marincola FM, Kuppen P, Ceccarelli M, Rinchai D, Chaussabel D, Miller L, Bedognetti D, Nguyen A, Sanborn JZ, Vaske C, Rabizadeh S, Niazi K, Benz S, Patel S, Restifo N, White J, Angiuoli S, Sausen M, Jones S, Sevdali M, Simmons J, Velculescu V, Diaz L, Zhang T, Sims JS, Barton SM, Gartrell R, Kadenhe-Chiweshe A, Dela Cruz F, Turk AT, Lu Y, Mazzeo CF, Kung AL, Bruce JN, Saenger YM, Yamashiro DJ, Connolly EP, Baird J, Crittenden M, Friedman D, Xiao H, Leidner R, Bell B, Young K, Gough M, Bian Z, Kidder K, Liu Y, Curran E, Chen X, Corrales LP, Kline J, Dunai C, Aguilar EG, Khuat LT, Murphy WJ, Guerriero J, Sotayo A, Ponichtera H, Pourzia A, Schad S, Carrasco R, Lazo S, Bronson R, Letai A, Kornbluth RS, Gupta S, Termini J, Guirado E, Stone GW, Meyer C, Helming L, Tumang J, Wilson N, Hofmeister R, Radvanyi L, Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE, Abraham TS, Xiang B, Magee MS, Waldman SA, Snook AE, Blogowski W, Zuba-Surma E, Budkowska M, Salata D, Dolegowska B, Starzynska T, Chan L, Somanchi S, McCulley K, Lee D, Buettner N, Shi F, Myers PT, Curbishley S, Penny SA, Steadman L, Millar D, Speers E, Ruth N, Wong G, Thimme R, Adams D, Cobbold M, Thomas R, Hendrickx W, Al-Muftah M, Decock J, Wong MKK, Morse M, McDermott DF, Clark JI, Kaufman HL, Daniels GA, Hua H, Rao T, Dutcher JP, Kang K, Saunthararajah Y, Velcheti V, Kumar V, Anwar F, Verma A, Chheda Z, Kohanbash G, Sidney J, Okada K, Shrivastav S, Carrera DA, Liu S, Jahan N, Mueller S, Pollack IF, Carcaboso AM, Sette A, Hou Y, Okada H, Field JJ, Zeng W, Shih VFS, Law CL, Senter PD, Gardai SJ, Okeley NM, Penny SA, Abelin JG, Saeed AZ, Malaker SA, Myers PT, Shabanowitz J, Ward ST, Hunt DF, Cobbold M, Profusek P, Wood L, Shepard D, Grivas P, Kapp K, Volz B, Oswald D, Wittig B, Schmidt M, Sefrin JP, Hillringhaus L, Lifke V, Lifke A, Skaletskaya A, Ponte J, Chittenden T, Setiady Y, Valsesia-Wittmann S, Sivado E, Thomas V, El Alaoui M, Papot S, Dumontet C, Dyson M, McCafferty J, El Alaoui S, Verma A, Kumar V, Bommareddy PK, Kaufman HL, Zloza A, Kohlhapp F, Silk AW, Jhawar S, Paneque T, Bommareddy PK, Kohlhapp F, Newman J, Beltran P, Zloza A, Kaufman HL, Cao F, Hong BX, Rodriguez-Cruz T, Song XT, Gottschalk S, Calderon H, Illingworth S, Brown A, Fisher K, Seymour L, Champion B, Eriksson E, Wenthe J, Hellström AC, Paul-Wetterberg G, Loskog A, Eriksson E, Milenova I, Wenthe J, Ståhle M, Jarblad-Leja J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A, Eriksson E, Milenova I, Moreno R. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. J Immunother Cancer 2016. [PMCID: PMC5123381 DOI: 10.1186/s40425-016-0173-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
13
|
Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, McMeekin DS, Moore KM. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol 2016; 142:225-30. [PMID: 27208536 DOI: 10.1016/j.ygyno.2016.05.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Revised: 05/16/2016] [Accepted: 05/17/2016] [Indexed: 01/22/2023]
Abstract
OBJECTIVE Women with primary platinum resistant (PPR) high grade serous ovarian cancer (HGSOC) are known to have a poor prognosis. Less is known regarding outcomes in patients with acquired platinum resistance (APR). The goal of this study was to evaluate survival in both PPR and APR patients. METHODS A retrospective review of HGSOC patients diagnosed between 2000 and 2010 was performed. Descriptive statistics summarized clinical characteristics and demographics. The Kaplan-Meier method estimated progression free survival (PFS) and overall survival (OS). The association of OS and clinical factors was modeled using Cox proportional-hazards. RESULTS Of the 330 patients identified, 81 (25%) had PPR. Of the remaining women, 55 (22%) developed APR. Median PFS of PPR patients was 4.2months and median OS was 17.8months. On multivariate analysis, the number of biologic agents received was the only predictor of OS. Patients with APR had a median PFS of 14.2months and a median OS of 56months. OS from the date of platinum resistance was 21.9months, though this was not different than PPR patients (p=0.19). Multivariate analysis found cancer stage and clinical trial participation to be associated with OS. CONCLUSIONS Platinum resistance confers a poor prognosis in the APR and PPR setting. The number of biologic agents received is the strongest predictor of OS among women with PPR. Cancer stage and clinical trial participation predicts OS in patients with APR. Providing opportunities to participate in clinical trials, especially those involving targeted therapy, should be a priority in these populations.
Collapse
Affiliation(s)
- Katrina Slaughter
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - Laura L Holman
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
| | - Eric L Thomas
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - Camille C Gunderson
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - Jacob K Lauer
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - Kai Ding
- Department of Biostatistics and Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - D Scott McMeekin
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| | - Kathleen M Moore
- Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
| |
Collapse
|
14
|
Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 2014; 134:478-85. [PMID: 25016924 PMCID: PMC5166425 DOI: 10.1016/j.ygyno.2014.06.029] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Revised: 06/25/2014] [Accepted: 06/28/2014] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Vascular endothelial growth factor (VEGF) receptor-mediated signaling contributes to ovarian cancer pathogenesis. Elevated VEGF expression is associated with poor clinical outcomes. We investigated ramucirumab, a fully human anti-VEGFR-2 antibody, in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Primary endpoints were progression-free survival at 6 months (PFS-6) and confirmed objective response rate (ORR). METHODS Women who received ≥ 1 platinum-based chemotherapeutic regimen and had a platinum-free interval of <12 months with measurable disease were eligible. Patients received 8 mg/kg ramucirumab intravenously every 2 weeks. RESULTS Sixty patients were treated; one patient remained on study as of September 2013. The median age was 62 years (range: 27-80), and median number of prior regimens was 3. Forty-five (75%) patients had platinum refractory/resistant disease. Thirty-nine patients (65.0%) had serous tumors. PFS-6 was 25.0% (n=15/60, 95% CI: 14.7-37.9%). Best overall response was: partial response 5.0% (n=3/60), stable disease 56.7% (n=34/60), and progressive disease 33.3% (n=20/60). The most common treatment-emergent adverse events possibly related to study drug were headache (65.0%; 10.0% Grade ≥ 3), fatigue (56.7%; 3.3% Grade ≥ 3), diarrhea (28.3%; 1.7% Grade ≥ 3), hypertension (25.0%; 3.3% Grade ≥ 3), and nausea (20.0%; no Grade ≥ 3). Two patients experienced intestinal perforations (3.3% Grade ≥ 3). Pharmacodynamic analyses revealed changes in several circulating VEGF proteins following initial ramucirumab infusion, including increased VEGF-A, PlGF and decreased sVEGFR-2. CONCLUSIONS Although antitumor activity was observed, the predetermined efficacy endpoints were not met.
Collapse
Affiliation(s)
- Richard T Penson
- Massachusetts General Hospital for the Dana-Farber/Harvard Cancer Center, Boston, MA, USA
| | - Kathleen M Moore
- University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | | | - Patricia Braly
- Hematology and Oncology Specialists, LLC, Marrero, LA, USA
| | | | - Hoa Nguyen
- Gynecologic Oncology Associates, Inc., Hollywood, USA
| | | | | | | | | | - Diane C Bodurka
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | | | - Yihuan Xu
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA
| | - Jonathan D Schwartz
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA
| | | |
Collapse
|
15
|
Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014; 25:1416-1421. [PMID: 24737778 DOI: 10.1093/annonc/mdu157] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Tivantinib (ARQ 197) is an orally available, non-adenosine triphosphate competitive, selective c-MET inhibitor. The primary objective of this study was to evaluate the safety, tolerability and to establish the recommended phase II dose (RP2D) of tivantinib and gemcitabine combination. PATIENTS AND METHODS Patients with advanced or metastatic solid tumors were treated with escalating doses of tivantinib (120-360 mg capsules) in combination with gemcitabine (1000 mg/m(2) weekly for 3 of 4 weeks). Different schedules of administration were tested and modified based on emerging preclinical data. Tivantinib was given continuously, twice a day (b.i.d.) for 2, 3 or 4 weeks of a 28-day cycle or on a 5-day on, 2-day off schedule (the day before and day of gemcitabine administration). RESULTS Twenty-nine patients were treated with gemcitabine and escalating doses of tivantinib: 120 mg b.i.d. (n = 4), 240 mg b.i.d. (n = 6) and 360 mg b.i.d. (n = 19). No dose-limiting toxicities were observed in escalation. The RP2D was 360 mg b.i.d. daily, and 45 additional patients were enrolled in the expansion cohort. Grade ≥3 treatment-related toxicities were observed in 54 of 74 (73%) patients with the most common being neutropenia (43%), anemia (30%), thrombocytopenia (28%) and fatigue (15%). There was one treatment-related death due to neutropenia. Administration of gemcitabine did not affect tivantinib concentration. Fifty-six patients were assessable for response. Eleven (20%) patients achieved a partial response and 26 (46%) had stable disease (SD), including 15 (27%) who achieved SD for over 4 months. Ten of 37 patients with clinical benefit had prior exposure to gemcitabine. CONCLUSION The combination of tivantinib at its monotherapy dose and standard dose gemcitabine was safe and tolerable. Early signs of antitumor activity may warrant further development of this combination in nonsmall-cell lung cancer, ovarian, pancreatic and cholangiocarcinoma. CLINICALTRIALSGOV IDENTIFIER NCT00874042.
Collapse
Affiliation(s)
- S Pant
- University of Oklahoma Health Sciences Center, Oklahoma City.
| | - M Saleh
- Georgia Cancer Specialists, Atlanta
| | - J Bendell
- SCRI, Tennessee Oncology, PLLC, Nashville
| | | | - S Jones
- SCRI, Tennessee Oncology, PLLC, Nashville
| | - C D Kurkjian
- University of Oklahoma Health Sciences Center, Oklahoma City
| | - K M Moore
- University of Oklahoma Health Sciences Center, Oklahoma City
| | | | | | | | - Y Chen
- BioMarin Pharmaceutical, Inc., Novato
| | | | | |
Collapse
|
16
|
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles DM, Tapper WJ, Thompson AM, Quinlan P, Jordan LB, Gillet C, Brentall A, Violette S, Weinreb P, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Abstract P4-15-01: Integrin avb6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The integrin avβ6 promotes migration, invasion and survival of cancer cells, but the biological relevance has yet to be ascertained in breast cancer. Our immunhistochemical analysis of over 2000 breast cancers has revealed that high expression of the protein for the integrin subunit beta6 (β6) is associated with very poor survival (HR = 1.99, P = 2.9×10-6) and increased metastases to distant sites (P = 0·02). This correlation was confirmed at the mRNA level via bioinformatic analysis of the 2000 women in the METABRIC cohort. Furthermore, co-expression of HER2 gave a significantly worse prognosis (HR = 3.43, P = 4×10-12), which we investigated further.
We report from in vitro studies that HER2-driven invasion is mediated by αvβ6 in an Akt2-dependent manner. Using the well-tolerated αvβ6-blocking antibody 264RAD in vivo we show that antibody-blockade of this integrin suppressed growth of BT-474 and MCF-7/HER2-18 human breast cancer xenografts similarly to trastuzumab alone (P<0.001), the antibody used for treating HER2-positive cancers (both 10mg/kg, bi-weekly). Moreover, when 264RAD was co-administered it significantly enhanced the ability of trastuzumab to suppress BT-474 tumor growth with a reduction in mean tumor volume of 94.8%+/-1.18% compared to 70.8%+/-5.98% observed with trastuzumab alone (P<0.0001) after 2 weeks treatment. This trend was reproduced even in the MCF-7/HER2-18 trastuzumab-resistant breast cancer tumors where a 76.24%+/-10.15% reduction was observed with combination therapy (P<0.0001) compared with only 44.62%+/-10.43% (P = 0.0006) and 46.6%+/-14.71% (P = 0.0004) reductions in final volume with 264RAD and trastuzumab respectively. The combination therapy was so effective it almost eradicated 100mm3 BT-474 tumors and completely eliminated small (10-20mm3) MCF-7/HER2-18 tumors.
264RAD or trastuzumab prolonged survival to a similar degree (14.3% and 33.33% treated mice alive after 100d, respectively, no significant difference) but again, when both drugs were combined 85.7% of mice were alive after 100d, a highly significant response compared with PBS (P<0.0001) or monotherapies (264RAD: P<0.0001, trastuzumab: P<0.0001). Post-therapy biochemistry revealed residual tumors expressed significantly reduced αvβ6, HER2, HER3 and downstream signaling molecules including Akt2 and Smad2, essentially a much lower ‘grade’ tumour.
Since 70% of women treated with trastuzumab either have, or develop resistance, we suggest combined targeting of αvβ6 and HER2 could provide an important novel therapy for thousands of women with breast cancer. In fact, over 39,000 American women annually (NIH statistics) will develop HER2+ breast cancers for which no specific therapies exist. Our data shows that in excess of 40% of these women with trastuzumab-resistant disease are also likely to express high levels of αvβ6.
Our data also suggest that routine determination of the level of expression of αvβ6 on breast cancers would be a valuable clinical tool as it identifies novel high-risk groups of women that require enhanced therapeutic intervention.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-15-01.
Collapse
Affiliation(s)
- KM Moore
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - GJ Thomas
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - SW Duffy
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - J Warwick
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - R Gabe
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Chou
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - IO Ellis
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - AR Green
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Haider
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - K Brouilette
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - A Saha
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Vallath
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - R Bowen
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - C Chelala
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - DM Eccles
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - WJ Tapper
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - AM Thompson
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Quinlan
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - LB Jordan
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - C Gillet
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - A Brentall
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Violette
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Weinreb
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - J Kendrew
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - ST Barry
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - IR Hart
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - JL Jones
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - JF Marshall
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| |
Collapse
|
17
|
Moore KM, Hart IR, Jones LJ, Marshall JF. P2-01-05: Integrin avb6 Mediates HER2−Driven Invasion in Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We have shown strong expression of integrin αvβ6 reduces the 5 year survival of HER2−positive breast cancers from 66% (HR 1.84) for moderate/low αvβ6 expressors to 54% (HR 2.18) in cases with strong expression (2063 cases, unpublished). This is in direct comparison to HER2/αvβ6-double negative cases, where strong αvβ6 expression reduces survival from 86% (HR 1.00) to 77% (HR 1.20). The biological mechanism underlying these observations was investigated in two isogenic breast cancer models: MCF-7/neo-1 and MCF-7/HER2−18 (a gift from Prof. M-C. Hung, USA) and MCF10A and MCF10A.CA1a.
Flow cytometry showed MCF-7/HER2−18 expressed high levels of both HER2 and αvβ6 whereas MCF-7/neo-1 expressed low levels of both receptors. MCF10A and MCF10A.CA1a both expressed high levels of αvβ6 whereas only MCF10A.CA1a expressed elevated levels of HER2. In charcoal-stripped (cs)-serum, comparing MCF-7/neo-1 and MCF-7/HER2−18, HRGβ1(1μM), which stimulates HER2/HER3 heterodimers, increased proliferation by 50.2%±9% (P=0.048) and 66.2%±5.5% (P=0.003), in MCF-7/neo-1 and MCF-7/HER2−18 cells respectively. In contrast, Herceptin reduced proliferation by 32.3%±13.4% (P=0.003) and 15.2%±3.4% (P=0.028), respectively. MCF10A and MCF10A.CA1a proliferation remained unchanged with HRGβ 1 treatment and antibody-blockade of αvβ6 did not affect proliferation of any cell line. (NB, in complete serum there was no effect on proliferation of any of the above treatments). Invasion through Matrigel of MCF-7/HER2−18 was inhibited by antibody blockade (10μg/ml) of αvβ6 (mAb 10D5; 38.6%±20.8%, P=0.005) or HER2 (Herceptin, 10μg/ml; 40.1%±28.6%, P=0.01). The same trend was observed in MCF10A.CA1a invasion (83%±30.2% (P=0.025) with 10D5 and 80.4%±8.7% (P=0.022) with Herceptin). Combination of both antibodies had no additional effect.
siRNA knockdown of αvβ6 or HER2 in MCF-7/HER2−18 and MCF10A.CA1a cells also reduced invasion to a similar extent as the blocking antibodies. This suggests that HER2 driven breast carcinoma invasion is mediated by αvβ6. To investigate this further HER2/3 was stimulated with HRGβ1, which consistently increased invasion by 111.5%±35.4% (P=0.011) in MCF-7/HER2−18 cells and by 57%±34% (P=0.042) in MCF10A.CA1a cells; an increase that was abrogated by co-treatment with 10D5 or Herceptin.
To determine the mechanism through which HER2 and αvβ6 co-operate we examined several signalling pathways. Analysis of total or activated Akt, ERKI/II, c-Jun or Src in the MCF-7 model showed no changes. However, elevated total and phospho-Stat3 in MCF-7/HER2−18 were observed and siRNA knockdown, or small-molecule inhibition, of Stat3 suppressed invasion of MCF-7/HER2−18 cells (54.5%±27.3% (P=0.008) and 55.3%±33.3% (P=0.01) respectively), possibly suggesting that activation of Stat3 may link αvβ6 and HER2 co-operative signalling in this model. Interestingly, Akt was constitutively phosphorylated in MCF10A.CA1a cells and, moreover, 10D5 reduced these levels suggesting αvβ6 may influence HER2 signalling via Akt in these cells.
These data confirm HER2−driven invasion is αvβ6-mediated and provide a mechanistic explanation for our clinical observations. We suggest HER2 and αvβ6 should be considered as dual targets for future therapy of some breast cancers.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-01-05.
Collapse
Affiliation(s)
- KM Moore
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - IR Hart
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - LJ Jones
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - JF Marshall
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| |
Collapse
|
18
|
Abstract
Understanding the scenarios whereby fishing gear entanglement of large whales induces mortality is important for the development of mitigation strategies. Here we present a series of 21 cases involving 4 species of baleen whales in the NW Atlantic, describing the available sighting history, necropsy observations, and subsequent data analyses that enabled the compilation of the manners in which entanglement can be lethal. The single acute cause of entanglement mortality identified was drowning from entanglement involving multiple body parts, with the animal's inability to surface. More protracted causes of death included impaired foraging during entanglement, resulting in starvation after many months; systemic infection arising from open, unresolved entanglement wounds; and hemorrhage or debilitation due to severe gear-related damage to tissues. Serious gear-induced injury can include laceration of large vessels, occlusion of the nares, embedding of line in growing bone, and massive periosteal proliferation of new bone in an attempt to wall off constricting, encircling lines. These data show that baleen whale entanglement is not only a major issue for the conservation of some baleen whale populations, but is also a major concern for the welfare of each affected individual.
Collapse
Affiliation(s)
- Rachel M Cassoff
- University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | |
Collapse
|
19
|
Warkentin TE, Sheppard JAI, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? ACTA ACUST UNITED AC 2006; 146:341-6. [PMID: 16310517 DOI: 10.1016/j.lab.2005.08.003] [Citation(s) in RCA: 183] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2005] [Revised: 07/31/2005] [Accepted: 08/02/2005] [Indexed: 10/25/2022]
Abstract
Heparin-induced thrombocytopenia (HIT) is usually caused by platelet-activating antibodies of immunoglobulin G class that recognize platelet factor-4 (PF4) bound to heparin or certain other polyanions. Commercial enzyme immunoassays (EIAs) for PF4/polyanion-reactive antibodies detect two immunoglobulin classes (IgA and IgM) besides IgG. To investigate whether the additional detection of these antibody classes improves or worsens assay operating characteristics, we compared the sensitivity and specificity of EIAs that detect these 3 immunoglobulin classes individually with that of a commercial EIA (Genetic Testing Institute, GTI), as well as a platelet-activation assay, the serotonin-release assay (SRA). We compared the operating characteristics of these 5 assays by evaluating 448 patients, in 14 of whom clinical HIT developed, who received either unfractionated or low molecular weight heparin in prospective studies that included systematic platelet-count monitoring and serologic evaluation for anti-PF4/polyanion antibodies. We found that the SRA and IgG and commercial EIAs had similar high sensitivity for HIT; however, diagnostic specificity (for unfractionated and low molecular weight heparin, respectively) varied considerably, as follows: SRA (95.1%, 97.2%) > IgG EIA (89.0%, 93.7%) > GTI EIA (74.2%, 87.6%). Additional detection of IgA and IgM antibodies by the GTI EIA worsened test specificity by detecting numerous nonpathogenic antibodies. Moreover, the frequency and magnitude of IgA and IgM antibody formation in non-HIT immune responses did not differ from that exhibited by patients in whom clinical HIT developed. We conclude that an EIA that detects anti-PF4/polyanion antibodies of only the IgG class has greater diagnostic usefulness in revealing clinical HIT than does an assay that also detects IgA and IgM class antibodies.
Collapse
Affiliation(s)
- Theodore E Warkentin
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
The stomachs of pigs (n=15,741) originating from 136 herds from the Australian states of Queensland, Western Australia, Victoria and New South Wales were examined at slaughter for the presence of oesophago-gastric ulcers (OGUs). Stomachs were categorised as being normal, hyperkeratotic, eroded, ulcerated, or having strictures. A questionnaire was distributed to piggery owners to identify factors associated with an above-average herd prevalence of OGU. Thirty percent of all pigs examined had OGU (median within-herd prevalence of 17%). The median within-herd prevalence in Victoria (53%) was significantly higher than in Western Australia (30%) or Queensland (7%). The prevalence of OGU in culled breeding animals was significantly higher than in porkers or baconers from the same herds. There was no difference between the prevalence of OGU in male and female pigs sampled from the same Western Australian herds. The relationship between OGU and herd and pig risk factors was assessed by random effects logistic-regression analysis. Herds with a high prevalence of OGU were more likely to feed ad libitum (OR=13.7), use automated feeding systems (OR=7.8), feed a pelleted ration (OR=384) and get water from a dam rather than from a bore or river (OR=3.8). Furthermore, for every change in the ration formulation for finisher pigs, the risk of OGU increased 1.5 times.
Collapse
Affiliation(s)
- I D Robertson
- Division of Veterinary and Biomedical Sciences, Murdoch University, Murdoch, WA 6150, Perth, Australia.
| | | | | | | | | | | |
Collapse
|
21
|
Lustig LR, Arts HA, Brackmann DE, Francis HF, Molony T, Megerian CA, Moore GF, Moore KM, Morrow T, Potsic W, Rubenstein JT, Srireddy S, Syms CA, Takahashi G, Vernick D, Wackym PA, Niparko JK. Hearing Rehabilitation Using the BAHA Bone-Anchored Hearing Aid: Results in 40 Patients. Otol Neurotol 2001; 22:328-34. [PMID: 11347635 DOI: 10.1097/00129492-200105000-00010] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE This study evaluates the U.S. experience with the first 40 patients who have undergone audiologic rehabilitation using the BAHA bone-anchored hearing aid. STUDY DESIGN This study is a multicenter, nonblinded, retrospective case series. SETTING Twelve tertiary referral medical centers in the United States. PATIENTS Eligibility for BAHA implantation included patients with a hearing loss and an inability to tolerate a conventional hearing aid, with bone-conduction pure tone average levels at 60 dB or less at 0.5, 1, 2, and 4 kHz. INTERVENTION Patients who met audiologic and clinical criteria were implanted with the Bone-Anchored Hearing Aid (BAHA, Entific Corp., Gothenburg, Sweden). MAIN OUTCOME MEASURES Preoperative air- and bone-conduction thresholds and air-bone gap; postoperative BAHA-aided thresholds; hearing improvement as a result of implantation; implantation complications; and patient satisfaction. RESULTS The most common indications for implantation included chronic otitis media or draining ears (18 patients) and external auditory canal stenosis or aural atresia (7 patients). Overall, each patient had an average improvement of 32+/-19 dB with the use of the BAHA. Closure of the air-bone gap to within 10 dB of the preoperative bone-conduction thresholds (postoperative BAHA-aided threshold vs. preoperative bone-conduction threshold) occurred in 32 patients (80%), whereas closure to within 5 dB occurred in 24 patients (60%). Twelve patients (30%) demonstrated 'overclosure' of the preoperative bone-conduction threshold of the better hearing ear. Complications were limited to local infection and inflammation at the implant site in three patients, and failure to osseointegrate in one patient. Patient response to the implant was uniformly satisfactory. Only one patient reported dissatisfaction with the device. CONCLUSIONS The BAHA bone-anchored hearing aid provides a reliable and predictable adjunct for auditory rehabilitation in appropriately selected patients, offering a means of dramatically improving hearing thresholds in patients with conductive or mixed hearing loss who are otherwise unable to benefit from traditional hearing aids.
Collapse
Affiliation(s)
- L R Lustig
- Department of Otolaryngology--Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland 21287, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Burrows SC, Moore KM, Lemkau HL. Creating a Web-accessible, point-of-care, team-based information system (PointTIS): the librarian as publisher. Bull Med Libr Assoc 2001; 89:154-64. [PMID: 11337946 PMCID: PMC31722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The Internet has created new opportunities for librarians to develop information systems that are readily accessible at the point of care. This paper describes the multiyear process used to justify, fund, design, develop, promote, and evaluate a rehabilitation prototype of a point-of-care, team-based information system (PoinTIS) and train health care providers to use this prototype for their spinal cord injury and traumatic brain injury patient care and education activities. PoinTIS is a successful model for librarians in the twenty-first century to serve as publishers of information created or used by their parent organizations and to respond to the opportunities for information dissemination provided by recent technological advances.
Collapse
Affiliation(s)
- S C Burrows
- Louis Calder Memorial Library, University of Miami School of Medicine, P.O. Box 016950, Miami, Florida 33101, USA
| | | | | |
Collapse
|
23
|
Moore KM. Anatomical references. J Biocommun 2001; 26:8-9. [PMID: 10989771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
|
24
|
Moore KM, Davis JR, Sato T, Yasuda A. Reticuloendotheliosis virus (REV) long terminal repeats incorporated in the genomes of commercial fowl poxvirus vaccines and pigeon poxviruses without indication of the presence of infectious REV. Avian Dis 2000; 44:827-41. [PMID: 11195637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Because of reticuloendotheliosis virus (REV) contamination in commercial poultry vaccines, polymerase chain reaction (PCR) assays have been described to increase the sensitivity of biological assays used to detect REV in vaccines. The PCR assay designed to amplify the long terminal repeat (LTR) region of REV identified REV LTRs in many of the commercial fowl poxvirus (FPV) vaccines evaluated. These commercial vaccines were not thought to be contaminated with replicating REV because of the lack of REV outbreaks, the lack of in vitro amplification, and lack of a serologic response to REV. As previously described, the FPV S vaccine strain is known to carry infectious integrated proviral REV, whereas FPV M vaccine strain and its derivatives carry integrated LTRs or remnants of REV proviral DNA inserted into the FPV genome. Another PCR assay designed to amplify the envelope gene of REV was used to verify that the envelope proviral gene was not present in REV LTR PCR-positive samples. Southern blot analysis with REV LTR probes hybridized to the 9-kb EcoRI genomic fragment of all FPV and pigeon poxviruses evaluated, whereas the envelope probe did not hybridize to any poxvirus genome. Sequence analysis of the 9-kb EcoRI fragment indicated that an integrated REV LTR exists in the 9-kb EcoRI of some poxvirus genomes. A new PCR assay designed to amplify integrated REV LTRs in the 9-kb EcoRI fragment identified complete and incomplete integrated REV LTRs in all FPV and pigeon poxvirus genomes evaluated.
Collapse
|
25
|
Abstract
Five independent populations (lines) of Drosophila melanogaster were selected for female starvation resistance. Females and males from the selected lines were relatively starvation resistant when compared to flies from five control lines. Moreover, flies from selected lines were resistant to other stresses: desiccation, acetone fumes, ethanol fumes, and paraquat (a source of oxygen radicals). Data from a variety of previous studies indicate an association between stress resistance and longevity. In this context, the present study addressed the question of whether flies from the stress-resistant lines were relatively long-lived. Replicate population cages from each selected and control line were used to assess longevity. Neither females nor males from the selected lines were relatively long-lived. In at least some cases, stress resistance may be necessary, but not sufficient, for longevity.
Collapse
Affiliation(s)
- L G Harshman
- School of Biological Sciences, University of Nebraska-Lincoln, 68588, USA.
| | | | | | | |
Collapse
|
26
|
DeLucas LJ, Moore KM, Long MM. Protein crystal growth and the International Space Station. Gravit Space Biol Bull 1999; 12:39-45. [PMID: 11541781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Protein structural information plays a key role in understanding biological structure-function relationships and in the development of new pharmaceuticals for both chronic and infectious diseases. The Center for Macromolecular Crystallography (CMC) has devoted considerable effort studying the fundamental processes involved in macromolecular crystal growth both in a 1-g and microgravity environment. Results from experiments performed on more than 35 U.S. space shuttle flights have clearly indicated that microgravity can provide a beneficial environment for macromolecular crystal growth. This research has led to the development of a new generation of pharmaceuticals that are currently in preclinical or clinical trials for diseases such as cutaneous T-cell lymphoma, psoriasis, rheumatoid arthritis, AIDS, influenza, stroke and other cardiovascular complications. The International Space Station (ISS) provides an opportunity to have complete crystallographic capability on orbit, which was previously not possible with the space shuttle orbiter. As envisioned, the x-ray Crystallography Facility (XCF) will be a complete facility for growing protein crystals; selecting, harvesting, and mounting sample crystals for x-ray diffraction; cryo-freezing mounted crystals if necessary; performing x-ray diffraction studies; and downlinking the data for use by crystallographers on the ground. Other advantages of such a facility include crystal characterization so that iterations in the crystal growth conditions can be made, thereby optimizing the final crystals produced in a three month interval on the ISS.
Collapse
Affiliation(s)
- L J DeLucas
- Center for Macromolecular Crystallography, University of Alabama at Birmingham 35294-0005, USA
| | | | | |
Collapse
|
27
|
Karpat KH, Moore KM. Al-Mughtaribun American Law and the Transformation of Muslim Life in the United States. International Migration Review 1997. [DOI: 10.2307/2547234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
28
|
Moore KM, Jackwood MW, Hilt DA. Identification of amino acids involved in a serotype and neutralization specific epitope within the s1 subunit of avian infectious bronchitis virus. Arch Virol 1997; 142:2249-56. [PMID: 9672590 PMCID: PMC7087143 DOI: 10.1007/s007050050239] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Localization of neutralizing, serotype specific epitopes of infectious bronchitis virus has been difficult because these epitopes are conformationally dependent. We identified amino acids involved in a serotype specific, conformationally dependent epitope by analysis of the S1 gene of 13 monoclonal antibody-neutralization-resistant mutants. Substitutions in the predicted amino acid sequence of these mutants were located at residues 304 and/or 386. Most of the substitutions at residue 304 were from threonine to isoleucine, whereas the substitutions at residue 386 were from arginine to proline, histidine, cysteine, or tryptophan. Based on this data, it appears that AA residues at 304 and 386 on the S1 glycoprotein are involved in a virus neutralizing serotype specific epitope.
Collapse
Affiliation(s)
- K M Moore
- Department of Avian Medicine, University of Georgia, Athens, USA
| | | | | |
Collapse
|
29
|
Gothard KM, Skaggs WE, Moore KM, McNaughton BL. Binding of hippocampal CA1 neural activity to multiple reference frames in a landmark-based navigation task. J Neurosci 1996; 16:823-35. [PMID: 8551362 PMCID: PMC6578660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The behavioral correlates of rat hippocampal CA1 cells were examined in a spatial navigation task in which two cylindrical landmarks predicted the location of food. The landmarks were maintained at a constant distance from each other but were moved from trial to trial within a large arena surrounded by static background cues. On each trial, the rats were released from a box to which they returned for additional food after locating the goal. The box also was located variably from trial to trial and was moved to a new location while the animals were searching for the goal site. The discharge characteristics of multiple, simultaneously recorded cells were examined with respect to the landmarks, the static background cues, and the box in which each trial started and ended. Three clear categories of cells were observed: (1) cells with location-specific firing (place cells); (2) goal/landmark-related cells that fired in the vicinity of the goal or landmarks, regardless of their location in the arena; and (3) box-related cells that fired either when the rat was in the box or as it was leaving or entering the box, regardless of its location in the arena. Disjunctive cells with separate firing fields in more than one reference frame also were observed. These results suggest that in this task a subpopulation of hippocampal cells encodes location in the fixed spatial frame, whereas other subpopulations encode location with respect to different reference frames associated with the task-relevant, mobile objects.
Collapse
Affiliation(s)
- K M Gothard
- Arizona Research Laboratory, Division of Neural Systems, Memory and Aging, University of Arizona, Tucson 85724, USA
| | | | | | | |
Collapse
|
30
|
Abstract
Four avian heterophil antimicrobial cationic peptides (Chicken Heterophil Peptides 1 and 2, and Turkey Heterophil Peptides 1 and 3) were evaluated for in vitro microbicidal activity against selected avian pathogens and human pathogens which are harbored by birds. At concentrations of 16-2 micrograms/ml, all four avian peptides effected a greater than 90% reduction in the survival of Candida albicans, Salmonella enteriditis, and Campylobacter jejuni. None of the peptides, including the known antimicrobial peptide protamine (used as a positive control), were able to reduce the survival of Pasteurella multocida by 90% at the maximum peptide concentration (16 micrograms/ml) tested. At 16 micrograms/ml, the turkey peptide THP3 did not effect a 90% reduction in survival of Bordetella avium, Escherichia coli, or Salmonella typhimurium, while all of the other peptides tested were effective at this concentration or less. This peptide, THP3, does not share the same homologous amino acid sequence shared by the other three peptides. Under our experimental conditions, none of the peptides neutralized Infectious Bronchitis Virus, an enveloped coronavirus of chickens.
Collapse
Affiliation(s)
- E W Evans
- Department of Veterinary Pathology, University of Georgia, Athens, USA.
| | | | | | | | | | | |
Collapse
|
31
|
El-Kabbani O, Green NC, Lin G, Carson M, Narayana SV, Moore KM, Flynn TG, DeLucas LJ. Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. Acta Crystallogr D Biol Crystallogr 1994; 50:859-68. [PMID: 15299353 DOI: 10.1107/s0907444994005275] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The crystal structures of porcine and human aldehyde reductase, an enzyme implicated in complications of diabetes, have been determined by X-ray diffraction methods. The crystallographic R factor for the refined porcine aldehyde reductase model is 0.19 at 2.8 A resolution. There are two molecules in the asymmetric unit related by a local non-crystallographic twofold axis. The human aldehyde reductase model has been refined to an R factor of 0.21 at 2.48 A resolution. The amino-acid sequence of porcine aldehyde reductase revealed a remarkable homology with human aldehyde reductase. The coenzyme-binding site residues are conserved and adopt similar conformations in human and porcine aldehyde reductase apo-enzymes. The tertiary structures of aldhyde reductase and aldose reductase are similar and consist of a beta/alpha-barrel, with the coenzyme-binding site located at the carboxy-terminus end of the strands of the barrel. The crystal structure of porcine and human aldehyde reductase should allow in vitro mutagenesis to elucidate the mechanism of action for this enzyme and facilitate the effective design of specific inhibitors.
Collapse
Affiliation(s)
- O El-Kabbani
- The University of Alabama at Birmingham, Center for Macromolecular Crystallography, 35294-0005, USA
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Moore KM, Jackwood MW, Brown TP, Dreesen DW. Bordetella avium hemagglutination and motility mutants: isolation, characterization, and pathogenicity. Avian Dis 1994. [PMID: 8002900 DOI: 10.2307/1591836] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Transposon mutagenesis was used to produce Bordetella avium mutants, which were screened for the lack of potential virulence factors, including a hemagglutinin, flagella, pili, and toxins. A mini-Tn10 transposon containing a kanamycin-resistance gene was introduced into the chromosomal DNA of the virulent 002/S isolate by electroporation. A hemagglutination-negative (HA-) mutant and a motility-negative mutant were obtained. Southern blot analysis showed that only the motility-negative mutant contained the transposon, whereas the HA- mutant was a spontaneous kanamycin-resistant mutant. Both mutants were stable in vitro and in vivo. Following inoculation of 2-week-old poults, the HA- mutant was determined to be less virulent than the 002/S parent, whereas the motility-negative mutant was similar in virulence to the 002/S parent. These results indicate that the hemagglutinin of B. avium is a virulence factor, but motility does not appear to contribute to virulence.
Collapse
Affiliation(s)
- K M Moore
- Department of Avian Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602
| | | | | | | |
Collapse
|
33
|
Moore KM, Jackwood MW. Production of monoclonal antibodies to the Bordetella avium 41-kilodalton surface protein and characterization of the hemagglutinin. Avian Dis 1994; 38:218-24. [PMID: 7980267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Production of monoclonal antibodies (MAbs) to Bordetella avium surface proteins led to further characterization of the hemagglutinin. Proteins obtained by homogenization of whole-cell B. avium were used to immunize mice for the production of monoclonal antibodies. Immunoprecipitation and Western blot techniques were used to determine the specificity of three MAbs, which all recognized the B. avium 41-kilodalton (kd) surface protein. In addition, all of the MAbs inhibited hemagglutination (HA) of guinea pig erythrocytes by B. avium. The 41-kd protein recognized by the MAbs was observed by the indirect immunofluorescence test and sodium dodecyl sulfate-polyacrylamide gel electrophoresis to bind to guinea pig erythrocytes. When HA-positive isolates of B. avium were treated with periodic acid, which cleaves carbohydrates from proteins, the isolates became HA-negative. Likewise, treatment of HA-positive B. avium isolates with proteinase K, which would also remove carbohydrates associated with proteins on the surface of the bacterium, inhibited HA. Considering these data, we suggest that the B. avium hemagglutinin is a carbohydrate closely associated with the 41-kd surface protein.
Collapse
Affiliation(s)
- K M Moore
- Department of Avian Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602-4875
| | | |
Collapse
|
34
|
El-Kabbani O, Sthanam L, Narayana VL, Moore KM, Green NC, Flynn TG, Delucas LJ. Crystallization and preliminary structure determination of porcine aldehyde reductase from two crystal forms. Acta Crystallogr D Biol Crystallogr 1993; 49:490-6. [PMID: 15299508 DOI: 10.1107/s0907444993004044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Aldehyde reductase from porcine kidney has been crystallized from buffered ammonium sulfate solutions. Two crystal forms are monoclinic, space group P2(1), with a = 56.2, b = 98.1, c = 73.2 A, beta = 112.5 degrees and a = 92.4, b = 62.1, c = 59.0 A, beta = 94.6 degrees. A third crystal form is hexagonal with a = b = 166.0, c = 66.0 A, alpha = beta = 90.0 degrees and gamma = 120.0 degrees. Molecular-replacement structure solutions have been successfully obtained for the two monoclinic crystal forms. The crystallographic R factor at 8-2.8 A resolution for the two monoclinic crystal forms is currently 0.23 and 0.25, respectively. There are two molecules per asymmetric unit related by a non-crystallographic twofold axis. The aldehyde reductase models are supported by the arrangement of the molecules in their respective unit cells and by electron densities corresponding to amino-acid side chains not included in the search structures.
Collapse
Affiliation(s)
- O El-Kabbani
- The University of Alabama at Birmingham, Center for Macromolecular Crystallography, 35294-0005, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Larsen CS, Schoeninger MJ, van der Merwe NJ, Moore KM, Lee-Thorp JA. Carbon and nitrogen stable isotopic signatures of human dietary change in the Georgia Bight. Am J Phys Anthropol 1992; 89:197-214. [PMID: 1443094 DOI: 10.1002/ajpa.1330890206] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Measurement of carbon and nitrogen stable isotope ratios (delta 13C and delta 15N) in samples of human bone collagen (n = 93) from a temporal series of four prehistoric (early preagricultural, late preagricultural, early agricultural, late agricultural) and two historic (early contact, late contact) periods from the Georgia Bight, a continental embayment on the southeastern U.S. Atlantic coast, reveals a general temporal trend for less negative delta 13C values and less positive delta 15N values. This trend reflects a concomitant decrease in emphasis on marine resources and increased reliance on C4-based resources, especially maize. This dietary reorientation is most apparent for the early agricultural sample (AD 1150-1300), coinciding with the Mississippian fluorescence in the eastern United States. There is, however, a shift toward the use of C3 (non-maize) foods during the last prehistoric period (AD 1300-1450), which is likely related to environmental stress and social disruption. A heavier use of maize and terrestrial resources in general after the establishment of mission centers on barrier islands is indicated. A reduced dietary breadth during the mission period may have contributed to the extinction of these populations in the eighteenth century.
Collapse
Affiliation(s)
- C S Larsen
- Department of Sociology and Anthropology, Purdue University, West Lafayette, Indiana 47907
| | | | | | | | | |
Collapse
|
36
|
el-Kabbani O, Narayana SV, Babu YS, Moore KM, Flynn TG, Petrash JM, Westbrook EM, DeLucas LJ, Bugg CE. Purification, crystallization and preliminary crystallographic analysis of porcine aldose reductase. J Mol Biol 1991; 218:695-8. [PMID: 1902521 DOI: 10.1016/0022-2836(91)90257-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Large crystals of porcine aldose reductase have been grown from polyethylene glycol solutions. The crystals are triclinic, space-group P1, with a = 81.3 A, b = 85.9 A, c = 56.6 A, alpha = 102.3 degrees, beta = 103.3 degrees and gamma = 79.0 degrees. The crystals grow within ten days to dimensions of 0.6 mm x 0.4 mm x 0.2 mm and diffract to at least 2.5 A. There are four molecules in the unit cell related by a set of three mutually perpendicular non-crystallographic 2-fold axes.
Collapse
Affiliation(s)
- O el-Kabbani
- University of Alabama, Center for Macromolecular Crystallography, Birmingham 35294
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
There have been claims that the use of lasers in surgery is associated with reduced operative blood loss, trauma, postoperative pain and improved postoperative mobility. With the development of sapphire probes capable of transmitting neodymium yttrium aluminium garnet (Nd: YAG) laser light, it is now feasible to perform direct-contact low-power laser surgery. In a small randomized controlled trial, we have compared cholecystectomy performed by conventional methods (n = 11) with the same operation performed by contact laser (n = 10). Operative time, blood loss, operative stability, analgesic requirement, mobility and response to the trauma of surgery were compared. The only differences between the two groups were a significantly increased wound infection rate (P = 0.051) in the laser surgery group and a significantly increased length of operating time (P = 0.001). Thus, the laser did not confer any advantage over conventional surgery.
Collapse
Affiliation(s)
- A C Steger
- Oldham and District General Hospital, UK
| | | | | |
Collapse
|